University of Wisconsin Milwaukee

UWM Digital Commons
Theses and Dissertations
August 2019

Obesity Suppresses Pigment Epithelium-Derived Factor and Alters
Pro-Tumorigenic Signaling Pathways in Prostate Cancer
Nizar Ahmed Khamjan
University of Wisconsin-Milwaukee

Follow this and additional works at: https://dc.uwm.edu/etd
Part of the Oncology Commons

Recommended Citation
Khamjan, Nizar Ahmed, "Obesity Suppresses Pigment Epithelium-Derived Factor and Alters ProTumorigenic Signaling Pathways in Prostate Cancer" (2019). Theses and Dissertations. 2207.
https://dc.uwm.edu/etd/2207

This Dissertation is brought to you for free and open access by UWM Digital Commons. It has been accepted for
inclusion in Theses and Dissertations by an authorized administrator of UWM Digital Commons. For more
information, please contact open-access@uwm.edu.

OBESITY SUPPRESSES PIGMENT EPITHELIUM-DERIVED FACTOR AND ALTERS
PRO-TUMORIGENIC SIGNALING PATHWAYS IN PROSTATE CANCER

by
Nizar A. Khamjan

A Dissertation Submitted in
Partial Fulfillment of the
Requirements for the Degree of

Doctor of Philosophy
in Health Sciences

at
The University of Wisconsin-Milwaukee
August 2019

ABSTRACT
OBESITY SUPPRESSES PIGMENT EPITHELIUM-DERIVED FACTOR AND ALTERS
PRO-TUMORIGENIC SIGNALING PATHWAYS IN PROSTATE CANCER

by
Nizar Khamjan
The University of Wisconsin-Milwaukee, 2019
Under the Supervision of Professor Jennifer A. Doll

Background: Pigment epithelium-derived factor (PEDF), a multifunctional
protein, is a potent tumor suppressor and anti-angiogenic factor. PEDF has been
identified as a novel regulator of lipid metabolism via binding and activating adipose
triglyceride lipase, which stimulates lipolytic pathways. PEDF-deficient mice develop
prostatic hyperplasia that progresses to cancer when these mice are fed a high fat diet
(HFD). PEDF expression is decreased in prostate cancer (PCa) patient tissues.
Conversely, PEDF treatment inhibits PCa growth in mouse models. Recently, our lab
has demonstrated that excess oleic acid (OA) treatment, an in vitro obesity model,
suppresses secreted PEDF expression in PCa cell lines (LNCaP, DU145, and PC-3)
and suppresses cellular PEDF expression in androgen-independent PCa cell lines
(DU145 and PC-3 cells). This is of interest because PCa patients who are obese are at
a higher risk of aggressive disease and more likely to die from the disease. However,
the molecular mechanisms through which excess OA down-regulates PEDF in vitro are
unknown. For the in vitro studies, we first investigated one OA receptor, G proteincoupled receptor 40 (GPR40), and tested if OA-mediated PEDF suppression was
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dependent on calcium (Ca2+) and/or peroxisome proliferator-activated receptor gamma
(PPARγ) signaling pathways. In addition, it is unknown if obese conditions suppress
PEDF in vivo within PCa tissues or within PCa xenograft tumors. Thus, we hypothesize
that excess lipids, in obesity and HFD microenvironments, alter lipid metabolism, which
in turn, increases pro-tumorigenic activity and decreases PEDF expression in PCa. To
study this hypothesis, we used an excess OA model in vitro and two in vivo PCa
models.

Methods: We treated RWPE-1, LNCaP, DU145, PC-3, and TRAMPC2 with
excess OA at 1 mM for 48 hours. Then, cells were counted, viability was assessed, and
PEDF levels were quantified by enzyme-linked immunosorbent assay (ELISA). For in
vivo studies, two obese models were used: (1) a xenograft model using the TRAMPC2
cell line injected in male WT mice and obese (ob/ob) mice and (2) male Pbsn-Cre+PTENfl/fl mice fed either a control diet (CD) or a HFD. All mice were in a C57Bl/6J
background. Blood samples, TRAMPC2 tumor xenograft tissue, mouse PCa tissues,
liver, and adipose tissues were collected. PEDF levels and pro-tumorigenic pathway
mediators were evaluated by ELISA and by Western blot, respectively.

Results: For the in vitro study, we found that OA did not interact with the GPR40
receptor and/or PPARγ to rescue secreted PEDF levels in LNCaP, DU145, and PC-3
cells. In Pbsn-Cre+-PTENfl/fl model, the prostate weight of HFD-fed mice was increased
as compared to CD-fed mice (P-value <0.042). In the TRAMPC2 xenograft model, we
iii

observed a significant increase in tumor volume and weight in TRAMPC2 tumors grown
in ob/ob mice as compared to tumors grown in lean mice (P-value <0.018). Tumor
PEDF levels were significantly decreased in TRAMPC2 xenograft tumors grown in
ob/ob mice compared to TRAMPC2 xenograft tumors grown in WT mice (P-value
<0.024). Lastly, in an effort to identify other signaling pathways altered in TRAMPC2
tumor tissues grown in ob/ob mice versus WT mice, we found a significant reduction in
superoxide dismutase 2 (SOD2; P-value <0.018) and serine palmitoyltransferase (SPT;
P-value <0.050). Interestingly, while previous studies showed that obesity increased
circulating PEDF, here we did not find an increase in circulating PEDF levels in ob/ob
mice with TRAMPC2 xenograft tumors as compared to WT mice. Moreover, circulating
PEDF levels were actually significantly decreased in HFD-fed Pbsn-Cre+-PTENfl/fl mice
compared to CD-fed Pbsn-Cre+-PTENfl/fl mice (P-value <0.001).

Conclusion: This is the first study to report that an obese microenvironment
suppresses circulating PEDF and suppresses PEDF, SOD2, and SPT in mouse PCa
tissues. Therefore, these data indicate that reduced PEDF, SOD2, or SPT levels could
be mechanisms of obesity-driven PCa progression.
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INTRODUCTION

Prostate cancer
The prostate is a 4 cm in width gland of the male reproductive system. The
primary function of the prostate gland is to produce seminal fluid that helps to protect
and activate the sperm. The prostate consists of three glandular regions: the peripheral
zone, central zone, and transitional zone. A fourth, non-glandular region, is the anterior
fibromuscular stroma [1]. The three most common diseases of the prostate are
prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer (PCa). PCa is a
leading men’s health concern because PCa is the most commonly diagnosed type of
cancer and the second leading cause of cancer-related death in men in the United
States [2]. In the US alone, it is estimated that about 174,650 men will be diagnosed
with PCa, and more than 31,620 patients will die from the disease in 2019 [3].
Approximately 95% of PCa are adenocarcinomas: 70% of which is localized in the
peripheral zone, 15-20% in the central zone, and 10-15% in the transitional zone [1], [4].
The early stages of PCa do not present with symptoms. However, in advanced stages
of PCa, there are symptoms, including difficulty urinating, sudden urge to urinate,
dysuria, and hematuria [5].

A variety of diagnostic tools and technologies are available to diagnose PCa. The
prostate specific antigen (PSA) blood test and the digital rectal examination (DRE) are
used as screening tools while transrectal ultrasound-guided biopsy (TRUS) is used as
the diagnostic test for PCa. An elevated PSA level may indicate the presence of PCa;
1

however, the test is not specific, as other diseases of the prostate and obesity affect
PSA levels [6]. In DRE, the prostate gland is physically examined to estimate the size of
the prostate gland and to identify if hard, lumpy, or abnormal areas are present in the
prostate; however, this physical exam does not provide an appropriate estimation for
the size of the prostate gland in obese patients as they are likely to have an enlarged
prostate [6]. A biopsy with histologic examination is necessary for a diagnosis of PCa. If
a biopsy confirms the presence of PCa, grading and staging systems are used for
histologic classification and reporting PCa. Other imaging techniques such as bone
scan and positron emission tomography scan are used to determine if PCa has
metastasized beyond the prostate for staging purposes.

The staging system is known as the TNM (tumor, node, and metastasis) system
that is used in many cancers including PCa [7]. Each category, i.e. tumor, node, and
metastasis, has subdivisions in each cancer type to allow precise staging of the cancer.
T describes the size of PCa and also indicates if the tumor has invaded into the nearby
seminal vesicle structure or other structures. N describes spread of PCa to regional
lymph nodes while M refers to metastasis of PCa to other parts of the body [7].

The Gleason grading system uses a 1–5 scale according to the appearance of
the glands and cells when stained with hematoxylin and eosin [8]. The most prominent
pattern and the second most common pattern are added together to give a Gleason
score of 2-10 [8]. A score that is 6 or over is considered PCa, and a score of 7 and
2

above indicates a clinically aggressive PCa [8]. If a diagnosis of PCa is confirmed,
prognosis and treatment options are dependent on several factors such as the stage
and grade of PCa [5]. Surgery, radiotherapy, hormone deprivation therapy,
immunotherapy, and chemotherapy are all options for treating PCa [5]. Even though
much progress has been made in the diagnosis and treatment of PCa, the etiology of
PCa remains largely unknown, but there are several risk factors have been firmly
established.

Both genetic and environmental factors contribute to PCa development [2]. Aging
is one of the most significant risk factors, with most cases of PCa occurring in men over
the age of 65 [2]. Approximately 80% of men, by the age of 80, will be diagnosed with
PCa, while PCa is very rarely diagnosed in men under the age of 40 [9]. PCa occurs
more commonly in men of African or Caribbean descent and less often in other races
[10]. This might be related to genetic polymorphisms, or allele frequencies, between
races. Another risk factor for PCa is a diet that is high in fats, red meat, and dairy
products, which is characteristic of a Western diet [10]. Obesity is often a consequence
of a Western / high fat diet (HFD), and most studies have shown an association
between obesity and increased risk of progression and death from PCa [11], [12].
Clinically, normal weight, overweight, and obesity are determined by using body mass
index (BMI) and waist/hip ratio systems [13]. BMI is the most widely used measure to
define obese individuals. Its calculation is based on weight in kilograms divided by
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square of height in meters (kg/m2). A score of 20-24.9 kg/m2 is normal weight; 25-29.9
kg/m2 is overweight; and, ≥ 30 kg/m2 is considered obese [13].

Vidal et al. examined the association between obesity and risk of low- and highgrade PCa among 6,427 men; 1,739 men (27%) were normal weight, 3,384 (53%) men
were overweight, and 1,304 (20%) were obese [14]. They concluded that obesity was
associated with low-grade PCa (OR, 0.79; P-value =0.01) and high-grade PCa (OR,
1.28; P-value =0.042) [14]. In a systematic review, a diet high in red meat, dietary fat,
and milk intake increased the risk of PCa while high fruit and vegetable intakes were
found to be preventive in PCa [15].

PCa, lipid metabolism, and obesity
Fatty acids (FA) are a type of lipid that is identified based on carbon chain length
or the number and position of double bonds in the carbon chain [16]. Carbon length
classification is divided as short-chain FA (< 6 carbons), medium-chain FA (6-12
carbons), long-chain FA (13-21 carbons), and very long chain FA (≥ 22 carbons) [16].
Saturated FA (SFA) have no double bonds and are mainly found in animal fat sources
such as butter, milk, meat, salmon, and eggs [16], [17]. Palmitic acid (PA) and stearic
acid (SA) are the most common SFA found in the oils and fats of animals. Unsaturated
FA that have only one double bond are called monounsaturated FA (MUFA), and FA
that have multiple double bonds are called polyunsaturated FA (PUFA) [16].
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Oleic acid (OA), which is an omega (ω)-9 FA, is the most common MUFA in the
body and in human adipose tissues [18]. The omega system identifies the position of
the double bond in MUFA [16]. The main sources of OA are vegetable oils such as
olive, canola, and sunflower oils, but it is also found in beef, chicken, eggs, nuts, and
seeds. ω-3 and ω-6 PUFA exist in high amount in nuts, olive, oil, diary, seeds, fish,
oyster, and shrimp [19]. Examples of ω-3 PUFA are alpha-linoleic acid (ALA),
eicosapentaenoic acid (EPA), and docosahexaenoic acid, while examples of ω-6 PUFA
are linolenic acid (LA) and arachidonic acid. Data obtained from epidemiological studies
on the risk of PCa associated with PUFA levels are inconsistent [20], [21].

In a prospective questionnaire study of 47,866 men, Leitzmann et al. evaluated
dietary LA intake with respect to PCa risk. They found that dietary LA intake was
unrelated to the risk of PCa [22]. In a case-control study of 89 PCa cases and 38
healthy controls from North Carolina, Godley et al. presented that increased LA, an ω-6
PUFA, isolated from erythrocyte membranes, are associated with a 5-fold increased risk
of PCa compared to men with low levels of LA (OR 3.54; P-value <0.04) [23].
Newcomer et al. isolated ALA, an ω-3 PUFA from erythrocyte membranes from PCa
patients (n= 67) and healthy controls (n= 156) from Washington State. They showed
that men with the highest levels of ALA ω-3 PUFA, compared to the men with the lowest
levels of ALA ω-3 PUFA, had a significantly increased risk of PCa (OR= 2.3; P-value
=0.01) [24]. A recent published study examined associations between PCa grades and
ω-3 FA levels in 157 men diagnosed with low-risk PCa. Moussa et al. found that EPA
5

(ω-3 FA) levels were elevated in prostate tissue, but not in red blood cells, and the EPA
elevation was associated with high-grade PCa (OR= 0.25; 95% CI= 0.08–0.79; P-value
=0.03) [25]. Yang et al. studied the relationship between PCa risk and the total levels of
ω-3 FA in serum samples obtained from PCa (n= 19), BPH (n= 24), and healthy
subjects (n= 21) [26]. They showed that total ω-3 PUFA serum levels were high in PCa
and BPH patients as compared to the healthy subjects [26]. When Yang et al. assessed
OA (MUFA), LA (PUFA), and PA (SFA) individually from the total levels of FA, they
observed no significant differences between PA, OA, and LA levels in all subject groups
[26].

In a nested case-control study conducted in men (n= 1061) from several
European countries, Aardestrup et al. investigated the relationship between the levels of
PA (SFA) extracted from plasma phospholipids and PCa development. They found that
the highest quintile of PA is correlated with the presence of localized and low-grade
PCa as well as a higher risk of high-grade PCa (OR 1.47; P-value =0.032) compared
with the lowest quintile of PA [27]. Together, epidemiological data regarding FA and risk
of PCa development are inconsistent. These divergences are common in
epidemiological studies because types of epidemiological studies, study design, study
size, analysis, and reporting are different between studies [28]. Although the stated
epidemiological studies were focused on linking FA to the risk of PCa, several mouse
studies have been performed to further explore the effects of excess lipids on PCa
progression.
6

Excess lipids that occur with obesity are stored as lipid droplets in cells. Lipid
droplets play crucial roles in protecting cancer cells through reduction of lipotoxic cell
damage, maintenance of energy and redox homeostasis, and regulation of FA
trafficking and distribution [29]. In addition, lipid droplets contribute to cancer cell
survival via protection against endoplasmic reticulum stress, membrane homeostasis,
and regulation of autophagy [29]. The effects of excess lipids and dietary FA on PCa
progression have been investigated through epidemiological and clinical studies as well
as in both in vitro and in vivo models of PCa.

Transgenic adenocarcinoma of the mouse prostate (TRAMP) and phosphatase
and tensin homolog (PTEN)-deficient mouse mice are two mouse models of PCa that
are widely used to study the molecular mechanisms of PCa progression [30]. Time to
tumor initiation, time to tumor penetration, and pathology of PCa tissues vary between
models [30]. TRAMP mice are generated by prostate-specific probasin (Pbsn) promoter
driving a viral oncogene, SV40 large T antigen, to develop PCa. These mice are
characterized by prostatic hyperplasia at 8-12 weeks, by mouse prostatic intraepithelial
neoplasia (mPIN) at 18-24 weeks, and by adenocarcinoma at 28 weeks [30]. Another
model is Pbsn-Cre+PTENfl/fl mice. These mice develop PCa due to Cre recombinase
activation under the prostate-specific Pbsn promoter [31]. These mice are well
characterized and develop murine prostatic intraepithelial neoplasia (mPIN) by 6 weeks
of age [31]. They progress from mPIN to invasive adenocarcinoma by 9 weeks of age,
7

and then to metastatic carcinoma by 12 weeks of age [31]. PTEN+/- mice are also used
to study the feature of hyperplasia and mPIN, but these mice take about 40-65 weeks to
develop adenocarcinoma [30].

Liu et al. examined whether HFD promoted PCa progression in PTEN+/- mice. Liu
et al. fed PTEN+/- mice with a HFD deriving 45% kcal from fat or a control diet (CD)
deriving 12% kcal from, beginning at 12 months of age for 3 and 6 months [32]. Liu et
al. found that HFD augmented the progression of mPIN in PTEN+/- mice [32]. In
addition, a HFD increased expression of phosphorylated Akt and mitogen-activated
protein kinase (MAPK) proteins by 2-fold in the prostate of PTEN+/- mice, but not in
PTEN+/+ mice. Similarly, the mRNA levels of β-catenin, peroxisome proliferator-activated
receptor (PPARγ), and sterol regulatory element binding proteins were elevated in HFDfed PTEN+/- mice, but not in PTEN+/+ mice [32]. Similar observations were reported in a
study by Chen et al [33]. In this study, Pbsn-Cre+PTENfl/fl mice were fed either a HFD
containing 60% kcal fat or a CD containing 17% kcal fat, starting at the age of 12
months for 3 months. A qualitative examination of the prostate tumors, isolated from
HFD-fed PTENfl/fl mice and stained with Oil Red O (ORO), displayed strong lipid
accumulation [33].

Another study used TRAMP mice fed either a Western diet containing 21.2% fat
and 0.2% cholesterol or a CD containing 4.5% fat and 0.002% cholesterol), starting at
the age of 8 weeks for 20 weeks [34]. An increase in body weight and larger tumors
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were observed in TRAMP mice fed a Western diet compared to TRAMP mice fed a CD
[34]. A higher grade and poorly differentiated adenocarcinomas were found in TRAMP
mice fed a Western diet as compared to a CD-fed mice [34]. In addition, the expression
levels of cyclin D1, used as a marker of increased proliferation and evaluated by
immunohistochemistry, were elevated in the ventral prostate of TRAMP mice fed a
Western diet compared mice fed a CD [34].

Ribeiro et al. used three types of obese C57Bl/6J mice (n= 6/group): diet-induced
obesity (DIO) mice; obese ob/ob mice, which are genetically deficient in leptin; and,
db/db mice, which are genetically deficient in leptin receptor [35]. They also included
WT mice on a standard laboratory diet. DIO mice were fed a HFD (45% kcal from fat),
starting at 21 days of age. All three obese mice, as well as WT mice, were used to
investigate the cellular growth of mouse prostate adenocarcinoma cell line (RM1), which
is syngeneic to C57Bl/6J mice [35]. RM1 cells at 3.0 X 105 cells were subcutaneously
inoculated, and tumor growth was monitored for 14 days [35]. The tumors from ob/ob
mice (2.82 ± 0.46 g) and DIO mice (2.78 ± 0.19 g) were significantly heavier than
tumors from wildtype (WT) mice (1.00 ± 0.24 g). However, the tumors from db/db mice
were smaller than tumors from WT mice. Together, the above studies are consistent in
demonstrating that obesity and/or a HFD accelerate PCa progression. However, while
several studies have examined the association between obesity and aggressive PCa,
little is known about molecular mechanisms that mediate obesity-driven PCa
progression.
9

In a study of 125 obese Caucasian men, serum pigment epithelium-derived
factor (PEDF) levels were significantly and positively correlated with BMI (r = 0.285; Pvalue =0.001) and with waist-to-hip ratio (r = 0.380; P-value <0.0001) [36]. Likewise,
Jenkins et al. found that the serum PEDF concentrations were correlated with BMI (r =
0.28; p-value =0.046) in control (n= 54) and in Type 2 diabetes patients (n= 96) [37].
With weight loss, circulating PEDF decreased, and the reduction of circulating
PEDF levels was significantly and positively associated with body weight loss
decreased BMI (r = 0.788; P-value =0.0001), waist circumference (r = 0.681; p-value
=0.0001), and hip circumference (r = 0.569; P-value =0.0001) [36].

To investigate this association, several mouse studies have been reported.
Crowe et al. used C57Bl/6J mice that were fed either a HFD (60% kcal from fat) or a CD
(4% kcal from fat) starting at eight-weeks old for 12 weeks [38]. The body weight of
HFD-fed mice was 35.8 ± 1.2 while the body weight of a CD-fed mice was 28.9 ± 0.6.
The plasma levels of PEDF were found to be significantly increased in HFD-fed mice (~
15 ng/ml) as compared to mice fed a CD (~ 4.9 ng/ml) [38]. The plasma PEDF levels
were positively correlated with increased body weight [38]. In addition, the PEDF mRNA
and protein levels were elevated in adipose tissues from HFD-fed mice as compared to
CD-fed mice [38]. Similar increases of PEDF mRNA and protein levels were observed in
the adipose tissue of ob/ob mice compared to WT mice [38]. However, MorenoNavarrete et al. showed that PEDF levels in adipose tissue did not alter circulating
10

PEDF levels, and subsequently, they found that the liver was the main source of
circulating PEDF levels [39].

Overall, these studies support an association between the increased circulating
PEDF and increased body weight. Although the elevated circulating PEDF is firmly
established in obese individuals, it is unknown which PEDF isoform is elevated and if it
has an anti-tumor activity. Also, the increased PEDF could be a compensatory
mechanism in response to increased body weight in obesity since its expression is
decreased with the body weight loss [36], [40]. No study has examined PEDF
expression in obese patients with PCa since previous studies were mainly focused on
understanding the molecular mechanisms by which obesity increases PEDF levels in
patients with other metabolic diseases such as diabetes.

PCa, pigment epithelium-derived factor, and signaling pathways
PEDF is a 418 amino acid, 50 kDa, multifunctional glycoprotein that was
originally identified in retinal-pigmented epithelium cells [41]. PEDF exists in both
intracellular and extracellular compartments and has cell-type specific functions. The
functional roles of PEDF includes acting as a potent anti-angiogenic factor, a tumor
suppressor protein, and a neuroprotective agent [42]. PEDF belongs to the non‐
inhibitory (serpin) family composed of two distinct groups. One group has a region
called the reactive center loop, and this region interacts with proteases, but the other
group does not have this active region [41]. The first group contains the family of
protease inhibitors and plays a crucial role in inflammation, blood coagulation, and
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extracellular matrix reconstitution. However, the second group, which includes PEDF,
functions in hormone transport, molecular chaperones, and tumor suppression [41].

Two isoforms of PEDF, named PEDF-1 and PEDF-2, have been identified, and it
seems that each isoform has a specific function [43]. PEDF-2 has more a potent antitumor activity than PEDF-1 [43]. Also, they have different charge and molecular mass:
PEDF-1 is 46,063 ± 13 Da and PEDF-2 is 47,176 ± 87 Da [43]. There are also two
synthetic peptides of PEDF that are a 34mer-residue fragment (amino acids 44-77) and
a 44mer-residue fragment (amino acids 78-121) [44], [45]. The 34mer PEDF peptide
plays a significant role in anti-cancer activities, including suppressing both tumorigenic
and angiogenic activities. The 44mer PEDF peptide is responsible for the neurotrophic
effects [44], [45]. In addition to the above PEDF functions, PEDF has been recently
identified as a novel regulator of lipid metabolism through binding and activating
adipose triglyceride lipase (ATGL) [46], [47]. This activity appears to be linked to the
44mer PEDF peptide since a study demonstrated that 44mer PEDF peptide treatment
decreased triglyceride (TG) accumulation via ATGL activation in cardiomyocytes [48].

In tissue specimens from PCa patients, there is a decrease in PEDF expression
that is correlated with metastasis and poor prognosis [49], [50]. Bryne et al. used lipid
depleted serum samples from PCa patients (n= 12) to perform proteomic analysis using
2-dimensional difference gel electrophoresis to identify potential biomarkers in PCa [51].
They found a significant decrease in serum PEDF levels with higher grades of PCa (P12

value =0.012) [51]. However, Ide et al. evaluated serum PEDF levels using an enzymelinked immunosorbent assay (ELISA) and found a statistically significant increase in
PEDF levels in PCa patients (n= 100) compared to normal subjects (n= 100) [52].
Additionally, increased plasma PEDF levels in PCa patients were positively correlated
with increasing Gleason score (P-value =0.014) [52]. In addition, Ide et al. found a
statistically significant positive association between BMI and serum PEDF in healthy
subjects (P-value =0.03), but not in PCa patients. These inconsistent findings in serum
PEDF may be due to sample preparation and assays used to evaluate PEDF levels.

Doll et al. demonstrated that PEDF knockout (KO) mice developed mPIN and
had increased prostate stromal microvessel density as compared to WT mice [49].
Recombinant PEDF (rPEDF) treatment of PC-3 tumor xenografts in male nude mice
decreased stromal vasculature and induced apoptosis [49]. Consistent with this, Guan
et al. found that treatment with an adenoviral vector-expressed PEDF decreased PC-3
xenograft tumor growth with decreased microvessel density as compared to adenovirallacZ construct or phosphate buffer saline treatment [53]. In PEDF-KO mice placed on a
HFD for 8 weeks, the mPIN progressed to cancer (Doll et al. unpublished data). In
addition, the PEDF-KO mice have increased lipid accumulation as demonstrated by
increased ATGL staining (Doll et al. unpublished data). Collectively, these data indicate
that PEDF functions as an anti-tumor protein and in the regulation of cellular lipid levels
in PCa.
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To understand how obesity affects PEDF levels in PCa cells, our lab used
excess OA treatment to simulate obesity in PCa cell lines in vitro. OA treatment
increased lipid accumulation in DU145 and PC-3 cells in a dose-dependent manner
(Doll et al. unpublished data). Our lab’s previous studies showed that the levels of
secreted PEDF were reduced in all PCa cell lines, LNCaP, PC-3, and DU145, and in a
normal prostate epithelial cell line, RWPE-1 treated with 1 mM OA, (Doll et al.
unpublished data). Additionally, 1 mM OA treatment further suppressed intracellular
PEDF levels in DU145 and PC-3 cells while no effects on intracellular levels of PEDF
were observed in RWPE-1 and LNCaP cells (Doll et al. unpublished observation).
Conversely, rPEDF treatment (10 and 50 nM) reduced intracellular TG levels in basal
and in OA-treated conditions, with a concomitant increase in lipolysis (TG breakdown) in
PC-3 cells (Doll et al. unpublished data). Likewise, PEDF’s function in TG lipolysis has
also been demonstrated in human cervical adenocarcinoma (HeLa) cells and
hepatocytes [46], [54]. In HeLa cells transfected with a PEDF expression vector, in the
presence of 0.4 mM OA, PEDF expression increased TG lipolysis [54]. PEDF has been
shown to activate ATGL resulting to increased TG breakdown in hepatocytes [46].
Taken together, these data support a role for PEDF in regulating lipid metabolism.

Currently, it is not known how excess OA suppresses PEDF in PCa cells. There
are several candidate pathways for this effect, including activation of the G proteincoupled receptor 40 (GPR40) and activation of peroxisome proliferator-activated
receptor gamma (PPARγ) as well as Wnt/ β-catenin signaling. GPR40, also known as
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free fatty acid receptor 1 (FFAR1), is found to be expressed at the mRNA level in both
DU145 and PC-3 cells [55], thus making it a potential receptor for OA-mediated activity.
Several studies report that medium- and long-chain free FA, including OA, are a ligand
for GPR40 [56]–[58].

GPR40 is known to signal through several pathways, including intracellular Ca2+
signaling. Alterations in intracellular Ca2+ signaling levels have been shown in
association with changes in PEDF levels in retinal and neuronal cells [59], [60]. In
ARPE19 cells, a human retinal pigment epithelial cell line, thapsigargin (1 µM)
increased cytoplasmic Ca2+ levels and reduced PEDF mRNA levels [59]. Another study
showed that rPEDF at 1.15 nM increased the intracellular levels of Ca2+ levels in
granule cells [60]. However, in isoproterenol-induced hypoxia, cardiomyocytes treated
with rPEDF at 10 nM reduced intracellular Ca2+ levels [61]. Although the stated studies
show an association between PEDF expression and intracellular Ca2+ levels, their
regulation in PCa is still not well understood.

Interaction of GPR40 with OA has been demonstrated to stimulate intracellular
Ca2+ in islet β-cells and muscle cells [56]–[58]. In islet β-cells, OA treatments at 1, 3, 5,
and 10 µM increased Ca2+ levels in the presence of 11.2 mM glucose; however,
inhibition of GPR40 by siRNA transfection impaired OA-induced Ca2+ levels in islet βcells [57]. More recently, and consistent with this, OA treatment at 10 µM increased
intracellular Ca2+ in human airway smooth muscle (HASM) cells while GPR4015

knockdown in HASM cells showed a decrease in Ca2+ in the presence of 10 µM OA
[62]. Similarly, OA treatments in concentration ranges 100-500 μM elevated cellular
Ca2+ levels via GPR40 in bovine neutrophils [63]. These studies reveal that activation of
GPR40 increases intracellular Ca2+ levels in some cell types. However, it still unknown if
OA interacting with GPR40-increased Ca2+ leading to PEDF suppression in PCa cells.
Therefore, we investigated if GPR40-induced intracellular Ca2+ activation is required for
PA-induced PEDF suppression in PCa.

Another possible molecular mechanism for OA-mediated effect is through PPARγ
activation. PPARγ is known as a master transcription factor controlling lipogenesis [64].
The expression levels of PPARγ were investigated in PCa clinical samples using IHC
staining, and PPARγ protein was detected in the nucleus and cytoplasm of PCa cells
and PIN, but no detection was observed in normal prostate tissue samples [65], [66]. In
an in vitro study, PPARγ expression was identified in LNCaP, DU145, and PC-3 cells
although the activation of PPARγ, using troglitazone or rosiglitazone at 5-10 µM, was
found to induce growth inhibition in these cells [67]. Interestingly, several studies
reported that the activity of PPARγ was affected by both OA and PEDF in other cell
types [68], [69], but their associated activity in PCa cells is still unknown. In 3T3-L1
adipocytes, OA treatments at 25, 50, and 100 µM increased PPARγ activity [70]. Ricchi
et al. found a similar observation in the effects of OA treatments at 0.66 mM and 1.32
mM on elevated PPARγ mRNA expression in hepatocellular carcinoma cell line
(HepG2) [71]. These two studies indicate that OA activates PPARγ in some cell types.
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Data obtained from the effects of PEDF treatment on PPARγ activity were mixed
[72], [73]. Wang et al. exhibited that in differentiating 3T3-L1 cells, 10 and 100 nM
rPEDF treatment inhibited PPARγ [72]. However, Hirsch et al. found that exogenous
rPEDF treatments at the dosages of 10, 50, and 100 nM increased the expression of
PPARγ in DU145 and PC-3 [61]. These studies suggest an association between PEDF
and PPARγ activity, but these activities are dependent on cell types. Herein, we
investigated the contribution of PPARγ activity on OA-mediated PEDF suppression in
PCa cells.

Wnt/β-catenin signaling (herein “Wnt signaling”) has been found to be increased
in advanced PCa [74] and to play a role in lipid regulation [75]. Additionally, PEDF has
been recently identified as an antagonist for Wnt signaling [76], [77]. High levels of Wnt1 and β-catenin were detected in LNCaP, DU145, and PC-3 while low levels were
observed in normal human prostate epithelial cells (PrEC) using immunocytochemical
analysis [74]. In PCa tissues, increased expression levels of Wnt-1 and β-catenin were
found to be associated with advanced and metastatic PCa, whereas their expression
was not detectable in normal prostate tissues [74]. Increased activity of β-catenin, as
measured by immunostaining for β-catenin, was associated with PCa progression and
invasive phenotype [78]. Low-density lipoprotein-related protein 6 (LRP6) and frizzled-1
are a co-receptor and receptor for Wnt signaling, respectively. Their interaction
stimulates phosphorylation of LRP6 which in turn releases β-catenin into cytoplasm [79].
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mRNA expression levels of LRP6 and Wnt ligand were upregulated in metastatic PCa
patient tissues compared to the primary tumor, and the expression levels were
associated with increased risk of recurrent PCa (hazard ratio= 6.955; P-value =0.0038)
[78].

Several studies showed that using silibinin and salinomycin, a chemical inhibitor
of LRP6, decreased DU145 and PC-3 cell proliferation through downregulation of Wnt
signaling [80], [81]. Elevated activity of Wnt signaling promotes lipid accumulation in the
liver of HFD-fed mice (60% kcal from fat) compared to mice fed a low-fat diet (10.5%
kcal from fat) [82]. Consistent with Wnt signaling-induced lipid accumulation, Wnt3a
treatment, which is a Wnt signaling activator ligand, increased the size and number of
lipid droplet (LD) formation in HeLa (cervical cancer), A431 (epidermoid carcinoma)
cells, and normal HepaRG hepatocytes. However, inhibition of Wnt signaling, using
dickkopf-related protein-1 (DKK-1) binding to Wnt co-receptor, prevented Wnt3ainduced LD in HeLa cells [83]. In addition, HeLa cells that were treated with Wnt3a
ligand in the presence of OA at 100 µg/ml showed an increase in the size and number
of LD compared to the Wnt3a treatment alone [83]. These results indicate that the
activation of Wnt pathways plays a significant role in LD formation. Data also determine
that Wnt signaling functions in lipid metabolism.

Interestingly, Park et al. and Protiva et al. have found that PEDF acts as an
antagonist for Wnt signaling [76], [77]. Using in vitro and in vivo models, they have
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shown that PEDF binds to LRP6, Wnt co-receptor, leading to inhibition of Wnt signaling
in the liver and retina [76], [77]. β-catenin levels were elevated in oxygen-induced
retinopathy and very low-density lipoprotein receptor-KO mice; however, when these
mice were intravitreally administered with rPEDF, β-catenin levels were decreased [76].
Park et al. displayed that after 2 h of treatment, rPEDF at 40 and 80 nM plus Wnt3a
agonist ligand reduced p-LRP6, total LRP6, and β-catenin in ARPE-19, a human retinal
pigment epithelial cells [76]. Protiva et al. support this finding in the liver by showing that
the activity of Wnt signaling and pLRP6 were increased in the liver of PEDF-KO mice
compared to WT mice; however, PEDF administration (25 µg/kg) reduced p-LRP6, but
not total LRP6 in PEDF-KO [77]. Additional in vitro studies supporting this observation
demonstrated that human hepatocellular carcinoma cell lines (HepG2 and Huh-7)
showed an increase in the activity of p-LRP6-associated with an increase in the activity
of β-catenin when these cells were transfected with siRNA PEDF [77].

Collectively, these studies demonstrate that PEDF binds to LRP6, Wnt coreceptor, resulting in inhibition of Wnt signaling in in vitro and in vivo models. The
relevance of PEDF interacting with LRP6-mediated Wnt signaling pathways in lipid
metabolism and PCa progression has yet to be revealed. Thus, our studies were
designed to investigate the association between PEDF and Wnt signaling in PCa.

Summary
Previous data indicated that excess OA treatment suppressed PEDF expression
while PEDF treatment stimulated lipolytic activity in PCa cells. However, the effects of
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excess lipids on PEDF expression in obese and HFD microenvironments in vivo are still
unclear in PCa. Additionally, the molecular mechanisms through which PEDF is downregulated by excess OA in vitro are currently unknown in PCa. Thus, we investigated an
OA receptor, GPR40, to determine its involvement in OA-mediated PEDF suppression
in PCa. We examined two potential intracellular signaling pathways, Ca2+ and PPARγ,
that could contribute to suppressing PEDF in OA-overloaded PCa cells. As stated
above, all of these molecular candidates are expressed in PCa, but the functional
effects and their interactions, in the context of obesity-induced PEDF suppression,
remain unclear. Therefore, this study was aimed to investigate the hypothesis that
excess lipids, in obesity and HFD microenvironments, alter lipid metabolism,
which in turn, increases pro-tumorigenic activity and decreases PEDF expression
in PCa. We used in vitro, ex vivo, and in vivo models of obesity to explore how PEDF
responds to excess lipids (Figure 1). Thus, our project had the potential to identify
PEDF suppression as a key mediator of excess lipid-mediated PCa progression which
could be targeted as an alternative strategy for therapeutic development in obese PCa
patients.
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Hypothesis and specific aims
The central hypothesis of this study was that excess lipids, in obesity and HFD
microenvironments, alter lipid metabolism, which in turn, increases pro-tumorigenic
activity and decreases PEDF expression in PCa. To test this hypothesis, the following
specific aims were proposed:

Figure 1. Proposed signaling pathways that are stimulated by an obese
micromovement leading to accelerated PCa progression. The functions of lipid
droplet were adopted from Petan et al. review article [29].

Specific Aim 1: Elucidate the molecular signaling pathways through which
excess OA, and other FA, suppress PEDF expression in vitro. Working hypothesis:
Excess OA activates GPR40-induced Ca2+ signaling and/or PPARγ signaling to
decrease PEDF expression in normal prostate and PCa cells.
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Specific Aim 2: Determine if excess lipids, in obesity and HFD
microenvironment, alter lipid metabolism by: (a) increased cyclin D1, (b) increased
SCD1, and (c) decreased PEDF. Working hypothesis: Pbsn-Cre+PTENfl/fl mice on HFD
and ob/ob mice with TRAMPC2 xenografts have increased intracellular lipid levelspromoted lipid accumulation in PCa tissues, which in turn, accelerate PCa progression
and reduced PEDF levels.
Specific Aim 3: Elucidate if obesity and/or HFD increase the expression of
PPARγ and Wnt signal pathways. Working hypothesis: Pbsn-Cre+PTENfl/fl mice on HFD
and ob/ob mice with TRAMPC2 xenografts have increased the expression of PPAR
and Wnt signaling pathways.
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MATERIALS AND METHODS
Cell culture
All cell lines were purchased from American type culture collection (ATCC,
Manassas, VA). RWPE-1 cells were derived from an adult human prostatic epithelial
cell line that was immortalized by transfection with human papillomavirus 18 [84].
LNCaP is a cell line derived from a supraclavicular lymph node metastasis of human
prostatic carcinoma [85]. PC-3 was established from a human prostatic
adenocarcinoma metastasis to bone [86], and DU145 is a cell line derived from a
human prostate adenocarcinoma metastasis to the brain [87]. TRAMPC2 cells are a
mouse PCa cell line derived from the TRAMP PCa model in a C57Bl/6J background
[88]. The LNCaP, PC-3, DU145, and TRAMPC2 cell lines were maintained in Roswell
Park Memorial Institute (RPMI) media (VWR, cat #. 10-040-cv) with 10% fetal bovine
serum (FBS, Fisher, cat. # 26140079) and 1% penicillin/streptomycin (P/S, VWR, cat. #
30-002-CI). RWPE-1 cells were grown in Keratinocyte complete media (Fisher, cat. #
17005042). All cells were incubated at 37°C in 5% CO2 for propagation.

Fatty acid preparation
FA (sodium oleate, sodium palmitate, or linoleic acid sodium salt) were dissolved
in 100% methanol (Sigma-Aldrich, cat. # O7501, P9767, and L8134, respectively). PA
only was heated at 55°C for 10 min to stimulate the solubility and to get a clear colorless
solution. Then, FA solution was sterilized using a 0.22 µm syringe filter unit (Sigma23

Aldrich, cat. # SLGV033RS). After filtration, 5 mM of FA was prepared in 7.5% FA-free
BSA (Sigma-Aldrich, cat. # A8806). To stimulate FA/BSA conjugate, the mixture was
then incubated at 37°C for 1 h with shaking. FA assay kit (Abcam, cat. # ab185433) was
used to validate the final concentration of FA/BSA conjugate. However, we were not
able to verify the concentration of FA/BSA conjugate because the mixture of FA/BSA
interfered with FA assay reagents.

Cell treatment
RWPE-1, DU145, PC-3, and TRAMPC2 cells were plated at 20,000 cell/cm2, but
due to their slow growth rate, LNCaP cells were plated at 40,000 cell/cm2 in a 10-cm
tissue culture dish. The cells were then incubated at 37ºC in 5% CO2 for 18-24 h to
ensure cell attachment. After the incubation, media were aspirated, and the cells were
washed with 1x phosphate buffer saline without calcium or magnesium (PBS, Fisher,
cat. # MT21-031-CV). PBS was aspirated, basal media with only P/S was then added (5
ml/10 cm dish), and the cells were incubated for 4 h. After the 4 h incubation, basal
media was aspirated, and cells were treated with various agents. For FA type
experiments, OA/BSA, PA/BSA, or LA/BSA conjugate at 0.25, 0.5, and 1 mM
concentrations were prepared in basal media with P/S, added to the cells, and
incubated for 48 h. For the cell signaling experiments, the cells were treated with 1 mM
liquid OA plus or minus 10 µM GPR40 antagonist (GW1100; cat. # 10008908) [89], 10
µM Ca2+ chelator (BAPTA-AM; cat. # 15551) [90], or 10 µM PPARγ antagonist
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(GW9662; cat. # 70785) [91]. GPR40 antagonist (GW1100), Ca2+ chelator (BAPTA-AM),
and PPARγ antagonist (GW9662) were purchased from Cayman chemical. GW9662
was dissolved in methanol while GW1100 and BAPTA-AM were dissolved in dimethyl
sulfoxide (DMSO). The cells were treated with 1 mM OA plus or minus each inhibitor of
interest or vehicle, and incubated for 48 h. After the incubation, cell samples were
collected as described below. The untreated group served as a control group for the
experiment. The vehicle (100% DMSO or 100% methanol) was included as an
additional control at an equivalent concentration to the inhibitor treatment group.

Conditioned media collection and concentration
After the 48 h incubation of the cells with treatment, conditioned media (CM)
were transferred from 10 cm dishes to 15 ml conical tubes, and 1X protease inhibitor
cocktail (PIC, Sigma-Aldrich, cat. # P8340) and phenylmethylsulfonyl fluoride (PMSF, 1
μM, Sigma-Aldrich, cat. # 93482) were added to a final dilution of 1:100. The collected
CM were centrifuged at 1000 x g for 10 min to precipitate cellular debris. Then, the
centrifuged CM were transferred to a clean 15 ml conical tube. Next, the CM were
filtered using a Millipore ultra-15 centrifugal filter device with a 3 kDa cutoff to
concentrate the protein (MilliporeSigma, cat. # UFC900324). The membrane of the
filtration device was pre-wet with 5 ml of sterile PBS and centrifuged at 4000 x g at 4°C
for 5 min. Then, 5 ml of CM and 5 ml of PBS were added to the membrane and
centrifuged at 4000 x g for 1-4 h. The final concentration of CM was approximately 1025

fold (500 µl). The concentrated CM was transferred to a 1.5 ml sterile siliconized
microfuge tube and stored at -80°C until use.

Proliferation and viability assay
After the 48 h FA treatment, the proliferation and viability of the cells were
quantified. Briefly, the cells were washed one time with PBS, and 1 ml of trypsin (Fisher,
cat. # MT25053CI) was added to detach cells. Then, 50 µl aliquot of the trypsin/cell
solution was taken and mixed with 50 µl of a 0.4% trypan blue exclusion dye. After a 5
min incubation, 15 µl of cell suspension was loaded onto a hemocytometer. The live cell
number (unstained cells) and dead cell number (blue cells) were counted. The cell
viability was calculated as a percentage by the formula: viability = (live cell number/total
cell number) x 100%. Proliferation data were normalized to the untreated group.

MTT proliferation assay
PCa cells were plated at 40,000 cell/cm2 in 96-well flat bottom and incubated
overnight to allow attachment. Then, cells were washed with PBS and incubate in basal
media media for 4 h. After 4 h, basal media were aspirated, experimental and vehicle
treatments were added. The cells with treatment media were incubated for 48 h. Next,
100 µ of basal media plus 10 µl of 12 mM MTT (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide) stock solution were added to each well and then
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incubated at 37°C for 4 h. Then, 85 µl of medium was aspirated, and 50 µl of DMSO
was added and mix. The plate was again incubated at 37°C for 10 min, absorbance was
read at 540 nm.

Cell lysate (CL) collection
The collected cells were pelleted by centrifugation at 1000 x g for 8 min, and the
supernatant was then discarded. Next, 350 µl of 1X cell lysis buffer (Sigma cat. #
9803S), which contained 1X PIC and 1 μM PMSF, was added. After that, the cells were
incubated on ice for 5 min. The cell mixture was transferred to a microfuge tube and
was vortexed for 30 sec. The sample was centrifuged at 14000 x g at 4°C for 10 min.
Finally, the CL was transferred to a siliconized microfuge tube and stored at -80°C until
used.

Protein quantification
Total protein in CL and CM samples was quantified using a standard Coomassie
dye-binding assay (Thermo Fisher cat. # 1856209). Briefly, for CL, 1-5 µl of cell lysate
was added to 490 µl of Coomassie reagent, and 1XPBS was added to bring the final
volumes to 500 µl. For CM sample analysis, 490 µl of Coomassie reagent was
transferred into centrifuge tubes, and 5 or 10 µl of CM was added. If 5 µl of CM was
used, then 5 µl of PBS was added. The standards were prepared with prediluted bovine
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serum albumin standards (Fisher, cat. # 23208). Then, 225 µl of samples and standards
were transferred to wells into a 96-well plate in duplicate. The absorbance at 595 nm
was measured in each well on a plate reader (Bio-Tek, KC4). The KC4 program
generated a standard curve and calculated the mean concentrations of each sample.

Human PEDF quantification
A human enzyme-linked immunosorbent assay (ELISA) was used per the
manufacturer’s instructions (Bioexpress, Frederick MD, PEDF ELISA kit cat. # PED613Human) to quantify PEDF levels in CM and CL samples. Briefly, 20 µg of total CL or CM
protein was added to the wells in a pre-coated anti-PEDF antibody 96-well plate, in
duplicate. The standards were prepared and added. The microtiter plate was covered
and incubated at 37°C for 1 h. The mixture was aspirated from each well and washed 5
times with wash buffer to remove unbound antigen. PEDF primary antibody was added
to the wells, and the microtiter plate was recovered and re-incubated at 37°C for 1 h.
The plate was washed again 5 times to remove the unbound antibodies. Streptavidin
peroxidase substrate was added to the wells and incubated at RT for 20 min. After the
incubation, sulfuric acid stop solution was added to stop the reaction. The absorbance
at 595 nm was measured in each well on a plate reader (Bio-Tek, KC4). The
concentrations of PEDF were calculated based on the standard curve, and values were
normalized to total protein.
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Mouse strains and diets
All experimental procedures were approved by the Institutional Animal Care and
Use Committee of University of Wisconsin-Milwaukee (UWM). All mice were housed in
a specific pathogen-free condition in the animal facility at UWM. Mice were kept in a
temperature-controlled room on 12 hours of light with 12 hours of dark cycle.

For a PCa tumor xenograft study, male C57Bl/6J WT and ob/ob mice (C57Bl/6J
background) were purchased from The Jackson laboratory. WT and ob/ob mice were
fed a standard chow diet (Teklad 7912), ad libitum. Ob/ob mice were used to mimic
human obesity as they are genetically deficient in leptin, a satiety hormone, and thus
overeat and become obese [92]. Mouse PCa TRAMPC2 cells, syngeneic to C57BL/6J
mice, were used in this tumor xenograft study. For the HFD study, we used male PbsnCre+-PTENfl/fl (C57Bl/6J background) mice, which develop PCa due to prostate-specific
knockout of the PTEN tumor suppressor gene.

DNA preparation
For the generation of Pbsn-Cre+-PTENfl/fl mice for the HFD study, we crossed
Pbsn-Cre+ mice with PTENfl/fl mice. These mice were bred and genotyped from a colony
maintained in the Doll lab. Mouse tail tissue was obtained using a razor blade at 21
days of age. For DNA extraction, we used Puregene DNA Purification Kit (Qiagen cat. #
158267). Briefly, cell lysis solution was chilled on ice, and lysis cocktail was prepared by
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combining 150 µl of ice-cold cell lysis solution and 0.75 µl of proteinase K solution. After
preparation of lysis cocktail, 150 µl was added to each tube containing a mouse tail
tissue and incubated at 55ºC overnight (at least 16 h) with shaking. Next, samples were
cooled to RT, and 50 µl of protein precipitation solution was added. The mixture was
vortexed at high speed for 20 seconds to mix. Then, samples were centrifuged at
16,000 x g for 6 min.

After centrifugation, the supernatant, containing the DNA, was transferred into a
clean 1.5 ml microfuge tube containing 150 µl of 100% isopropanol. The samples were
gently mixed by inverting the tube and were then centrifuged at 16,000 x g for 10 min.
The supernatant was poured off, and the tube was drained using clean absorbent
paper. Next, 150 µl of 70% ethanol was added to each tube, and the tubes were gently
mixed by inverting them. Again, the samples were centrifuged at 16,000 x g for 10 min.
Then, the 70% ethanol was poured off, and the tube was again drained using clean
absorbent paper. The samples were allowed to air dry for 15 min. After that, 100 µl DNA
hydration solution was added to each tube. The samples were incubated at RT
overnight. DNA samples were stored at 4°C until use.

Pbsn-Cre and PTENfl/fl allele genotyping
The presence of the Pbsn-Cre transgene and PTENfl/fl gene allele was validated
using polymerase chain reaction (PCR). All primers were purchased from Invitrogen
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(Carlsbad, CA) and reconstituted at 100 µM using sterile Tris-EDTA buffer. The primers
for Pbsn-Cre and PTENfl/fl PCR reaction are shown in Table 1. We used the MJ
Research PTC100 thermal cycler (Watertown. MA). PCR cocktail was prepared for
each reaction (Table 2 and Table 3). Next, 24 µl of PCR cocktail of Pbsn-Cre was
added to each tube, and 1 µl of tail DNA was added. The Pbsn-Cre PCR program is
shown in Table 4. For the PTEN reaction, and 23 µl of PCR cocktail was added to each
tube, 2 µl of tail DNA was added to appropriate tube. The PTEN PCR program is
presented in Table 5.

Table 1. Primer sequences for PCR
P021 (Pb-Cre-F)

5'- CTG AAG AAT GGG ACA GGC ATT G -3'

C031 (Pb-Cre-R)

5'- CAT CAC TCG TTG CAT CGA CC -3'

OIMR9554 (PTEN-F)

5'- CAA GCA CTC TGC GAA CTG AG -3'

OIMR9555 (PTEN-R)

5’- AAG TTT TTG AAG GCA AGA TGC -3'
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Table 2. Pbsn-Cre genotyping PCR reaction
Component:

PB-Cre (in ml) for one reaction

mQH2O

18.25

10x PCR buffer

2.5

50 mM MgCl2

1

10 mM dNTP mix

0.5

20 μM primer - C031

0.625

20 μM primer - P021

0.625

5 U/μl JumpStart Taq

0.5

TOTAL

24 ml

Table 3. PTENfl/fl genotyping PCR reaction
Component:

PTEN (in ml) for one reaction

Water

9.3

Midsci Master Mix*

12.5

20 μM primer – OIMR0554

0.6

20 μM primer – OIMR0555

0.6

TOTAL

23 ml

* Bullseye Taq Plus Master Mix with red dye was purchased
from MidSci (cat #. Betaqr-r).
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Table 4. Pbsn-Cre PCR program using MJ Research PTC100 thermal
cycler
Step

PCR process

Temperature (°C)

Time

1

Initial denature

94

3 min

2

Denature

94

30 sec

3

Annealing

60

30 sec

4

Elongation

72

30 sec

5
6

Repeat step 2-4, 34 more times (35 cycles total)
Elongation

7

72

3 min

Hold, 10°C, indefinitely

Table 5. PTEN PCR program using MJ Research PTC100 thermal cycler
Step

PCR process

Temperature (°C)

Time

1

Initial denature

94

3 min

2

Denature

94

30 sec

3

Annealing

60

1 min

4

Elongation

72

1 min

5
6
7

Repeat step 2-4, 34 more times (35 cycles total)
Elongation

72
Hold, 10°C, indefinitely
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2 min

TRAMPC2 xenograft study
Ob/ob (n= 40) and WT (n= 40) mice were ear-tagged for unique identification. At
3.5 months of age, the mice were anesthetized using 1-3% Isoflurane inhalation in a
desiccator jar, and 5 X 106 TRAMPC2 cells were subcutaneously injected into the right
flank of WT and ob/ob mice. The mice were monitored for tumor growth. Once palpable
tumors were present, the tumors were measured weekly (longest length and
perpendicular diameter recorded). Tumor volume was then calculated using the
following formula: volume = [(length x width2) x 0.52] [93]. Once the largest tumors
reached 20 mm in diameter, all mice injected with TRAMPC2 xenografts were
euthanized. Tumor tissues were harvested at approximately 6 months of age. Due to
variability in tumor take rate and time to tumor initiation, only a subset of WT mouse
tumor (n= 10) and ob/ob mouse tumor (n= 20) was used in the TRAMPC2 xenograft
study. This subset was chosen based on the same tumor initiation time frame.

Pbsn-Cre+-PTENfl/fl HFD study
Pbsn-Cre+-PTENfl/fl mice were ear-tagged at weaning (21 days of age) for unique
identification, and a piece of tail tissue was obtained as described above to confirm
genotype. The mice were fed either a HFD (Harlan Teklad diet TD.06414, 60% kcal
from fat; n= 18) or CD (Table 6; Harlan Teklad diet TD.08810; 16.8% kcal from fat; n=
18) starting at 2 months of age and were sustained for 4 months. Three to four mice
were housed per cage. Food intake was measured weekly, and mouse weights were
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also recorded weekly. At 6 months of age, serum was collected, and subcutaneous
adipose tissue, epididymal fat pad, liver, and prostate lobes were harvested.

Table 6. Nutrient and energy information of the
control diet and high-fat diet
Diet

CD (% kcal)

HFD (% kcal)

Protein

22.3

18.3

Carbohydrate

60.9

21.4

Fat

16.8

60.3

Component

Blood collection and serum preparation
Blood samples were collected from both in vivo PCa models at harvest using an
ocular sinus (retro-orbital) technique. Briefly, mice were placed in a desiccator jar
containing 1-3% Isoflurane within a fume hood. When the mice were anaesthetized,
blood samples were collected by inserting a pasteur pipette into the medial canthus of
the eye and was gently moved into the sinus. When sufficient blood was obtained, the
pasteur pipette was removed. A guaze pad was gently pressured to the mouse eye to
facilitate hemostasis. The collected blood was dispensed into 1.5 ml microfuge tubes
and kept at RT for at least 30 min to allow clot to form. Next, the clotted blood was
centrifuged at 860 x g at RT for 10 min to remove cellular components. The serum was
transferred into a 1.5 ml siliconized tube and was stored at -80°C until use.
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Tissue harvest
To harvest mouse tissues, following blood collection, mice were returned to 1-3%
Isoflurane to euthanize them by anesthesia overdose, followed by a cervical dislocation
to ensure death. For TRAMPC2 xenograft study, tumor tissues were harvested and
weighed. For Pbsn-Cre+-PTENfl/fl mice HFD study, subcutaneous adipose tissue,
epididymal fat pad, liver, and prostate lobes were harvested. Both the prostate and
epididymal fat pads were weighed. All collected tissues were flash frozen in liquid
nitrogen and stored at -80°C until processing.

Tissue homogenization
A portion of TRAMPC2 tumor tissues was weighed and placed in a 1.5 ml
microfuge tube on ice. For the Pbsn-Cre+PTENfl/fl model, all prostate lobes (ventral,
dorsolateral, and interior) and periprostatic fat tissues were weighed. To homogenize
the tissues, we used a tissue extraction reagent Ι (TER) (Invitrogen, Carlsbad, CA Cat #
FNN0071). The volume of TER was calculated based on the total tissue weight (1 ml of
TER per 0.1 g of tumor tissue) with 1X PIC, PMSF, and PhosSTOP (Sigma-Aldrich, cat.
# 4906845001). The estimated volume of prepared TER solution was added to tumor
tissues. Then, tumor tissues were homogenized using a motorized disposable pestle
while kept on ice. After homogenization, samples were centrifuged at 10,000 RPM for 5
min. The supernatant was transferred into a 1.5 ml siliconized tube and kept on ice.
Total protein content was quantified using a Coomassie dye-binding protein assay as
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described under the protein quantification section using 10 µl tissue homogenate and
490 µl of Coomassie reagent.

Western blot assay
Western blot analysis was performed on the homogenized TRAMPC2 tumor
tissue and on the PCa cell line CL samples. Primary antibodies, purchased from Cell
Signaling Technology (CST; Danvers, MA and Abcam), were cyclin D1 (cat. # 2922),
PPARγ (cat. #2430), pβ-catenin Thr41/Ser45 (cat. # 9565), β-catenin (cat. # 9562), Ecadherin (cat. # 3195), LRP6 (cat. # 3395), pLRP6 ser1490 (cat. # 2568), JNK (cat. #
3708), pJNK Thr183/Tyr185 (cat. # 4668), pERK1/2 Thr202/Tyr204 (cat. # 4377),
AMPKα (cat. # 2532), pAMPKα Thr172 (cat. # 2535), and SOD2 (cat. # 13194). For a
loading control, pan-actin (cat. # 8456) or GAPDH (cat. # 3683) was used. Serine
palmitoyltransferase (SPT) was purchased from Abcam (cat. # ab23696). Secondary
antibody conjugated to horseradish peroxidase (HRP) was purchased from CST (cat. #
7074).

Thirty µg of CL protein was separated by SDS-polyacrylamide gel
electrophoresis [SDS-PAGE; 4-20% precast acrylamide gel (BIO-RAD, Hercules, CA)].
For a size standard, we used a pre-stained protein marker (MIDSCI, Valley Park, MO
cat. # BEPAR or FPL1). Electroblotting was used to transfer the separated proteins from
the gel to a polyvinylidene difluoride membrane (PVDF; GenHunter, Nashville, TN cat. #
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88518). The PVDF membrane was blocked with either 5% non-fat dry milk or 5% BSA
(Thermo Scientific cat. # BP1600-100). After hybridization with primary antibody, the
appropriate secondary antibody, conjugated to HRP, was added. The proteins of
interest were then detected using a chemiluminescent detection system (Thermo
Scientific; cat #. 34095 or 34580) through enzymatic reaction with HRP. The blot was
then exposed to X-ray film to obtain an autoradiogram for a permanent record.
Densitometry (ImageJ, NIH) was performed on the resulting bands of the correct
molecular weight for semi-quantitative analysis.

Mouse PEDF quantification
The concentration of mouse PEDF protein was measured using a Mouse PEDF
ELISA following the manufacturer’s protocol (MyBioSource, San Diego, CA cat. #
MBS2887741). All reagents were brought to the RT and were prepared per the
manufacturer’s instructions. Standard reagent was reconstituted in 1 ml of sample
diluent and was placed on an orbital rotator to ensure complete dissolution. Serial
dilutions of standards were prepared. For TRAMPC2 tumor tissues, 0.05 µg of total
protein/well was prepared in sample diluent before the samples were loaded into wells
in duplicate in 96-well plate. Mouse serum samples were diluted at 1:20 in sample
diluent before they were loaded into the ELISA plate in duplicate.
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Next, 100 µl of standards and samples were loaded into wells in duplicate. Then,
the plate was covered and incubated at 37°C for 2 h. After 2 h of incubation, standards
and sample liquids were aspirated from each well. Then, 100 µl of Detection Solution A
was added to each well. The plate was sealed and incubated at 37°C for 1 h. After
incubation, the detection solution A was aspirated, and the plate was washed with 1X
wash buffer that left in wells for 1-2 min. The wash buffer was aspirated, and the wash
was repeated for a total of three washes. After washing, 100 µl of Detection Solution B
was added to each well. The plate was sealed and incubated for 1 h. The plate was
washed again for a total of 5 times. Next, 90 µl of substrate solution was added to all
wells, and the plate was covered and incubated 37°C for 10-20 min. 50 µl of stop
solution was added to each well. The plate was read at 450 nm using the Synergy HT
plate reader (Biotek, Winooski, VT). The unknown PEDF levels of each sample were
calculated from the standard curve.

Serum mouse leptin quantification
The serum concentration of leptin was measured using Mouse/Rat Leptin
Quantikine ELISA Kit per the manufacturer’s protocol (R&D system, Minneapolis, MN
cat. # MOB00). Serum of CD-fed Pbsn-Cre+PTENfl/fl mice was diluted 20-fold into
calibrator diluent RD5-3 while serum of HFD-fed Pbsn-Cre+PTENfl/fl mice was diluted
100-fold into calibrator diluent RD5-3. The Mouse/Rat leptin standard was reconstituted
with 2 ml of calibrator Diluent RD5-3. Then, 50 µl of assay diluent RD1W was added to
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each well followed by adding 50 µl of standard, control, and samples. Next, the plate
was gently mixed by tapping the plate frame for 1 min, then covered with an adhesive
strip, and incubated at RT for 2 h. After incubation, the plate was washed with 1X wash
buffer for five times, and 100 µl of Mouse/Rat leptin conjugate was added to each well.
Then, the plate was covered with an adhesive strip and incubated at RT for 2 h. After
that, the plate was washed with 1X wash buffer for 5 times, and next, 100 µl of substrate
solution was added to all wells. Then, the plate was protected from the light and
incubated at RT for 30 min. Then, 100 µl of stop solution was added to each well, and
absorbance was determined at 450 nm using the Synergy HT plate reader (Biotek,
Winooski, VT). The unknown concentration of leptin was calculated from the generated
standard curve.

Statistical analysis
All in vitro experiments were repeated at least twice with similar results. Student’s
t-test was used to determine changes on cell proliferation (total cell number, live cell
number, and viability), and PEDF levels between groups. If a data set included values
that were above or below the detection limit of the assay, a Mann–Whitney U test was
used. One-way ANOVA was performed to determine significant differences in doseresponse experiments. If a significant difference in group means was revealed by oneway ANOVA, Post-hoc Bonferroni procedure was used for pairwise comparison.
Statistical significance was set at p < 0.05, and data from the in vitro study were
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presented as the mean ± standard deviation of the mean (SD) while data from the in
vivo study were presented as the mean ± standard error of the mean (SEM).

41

RESULTS

INVESTGATION OF SIGNALING PATHWAYS MEDIATING FATTY ACID-INDUCED
PEDF SUPPRESSION IN PCA CELLS IN VITRO

The effects of FA on the proliferation and viability of normal prostatic epithelial
cells and PCa cells
In previous studies, a stimulatory growth response to excess OA was observed in
two androgen-independent PCa cells, PC-3 and DU145; however, normal prostatic
epithelial cells, RWPE-1, and androgen-dependent PCa cells, LNCaP, did not show this
stimulatory growth response to excess OA (Doll et al. unpublished data). Particularly,
OA at the dosage of 0.1-1.5 mM stimulated the proliferation of PC-3 and DU145 cells
after 48 h of incubation in a concentration-dependent manner compared to untreated
group (Doll et al. unpublished data). As published studies showed that OA treatments
interact with GPR40 receptor leading to activated cytoplasmic Ca2+ and/or PPARγ [57],
[94], we wanted to investigate whether these molecules are necessary for OA to exert
its pro-proliferative effects on PCa cells (Figure 1). In this study, the cells were treated
with 1 mM OA, ready to use from Sigma-Aldrich, in the presence or absence of GPR40
inhibitor (GW110), Ca2+ chelator (BAPTA AM), or PPARγ inhibitor (GW9662) at 10 µM.
OA treatment at 1 mM was used to simulate obesity in vitro (Doll et al. unpublished
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study). Then, proliferation and viability were assessed using a direct cell count with
trypan blue exclusion dye, respectively.

Consistent with previous studies, total live numbers of LNCaP cells were not
changed with OA plus or minus the GPR40 inhibitor, GW1100, treatment at 10 µM
(Figure 2A). Likewise, these treatments did not change viability in LNCaP cells (Figure
2B). OA alone or with GW1100 inhibitor did not change DU145 cell proliferation and
viability (Figure 3A and 3B). This observation is inconsistent with our lab previous data
as proliferation was shown to increase with 1 mM OA. Proliferation and viability of
RWPE-1 and PC-3 cells were also tested with OA alone or with the GPR40 inhibitor.
However, the proliferation data were not presented since large variances within
experiments was found. The current data suggest that OA treatment alone or with
GPR40 inhibitor did not affect LNCaP and DU145 cells.

Figure 2. Proliferation and viability were not affected in LNCaP cells treated with 1 mM oleic acid
(OA) +/- GPR40 inhibitor. LNCaP cells were seeded at 40,000 cells/cm2 in tissue culture dishes. The
cells were incubated overnight and were then treated with 1 mM OA +/- 10 µM GW110 or vehicle (DMSO;
5.2 µl). After 48 h of incubation, cells were collected, and proliferation (A) and viability (B) were assessed
by hemocytometer with trypan blue dye. No significant changes were observed among groups compared
to untreated group. Proliferation data are presented as fold over the untreated control group. Both data
sets are presented as the mean ± SD. The experiment was repeated at least twice with similar results.
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Figure 3. Proliferation and viability levels are not changed in DU145 cells treated with 1 mM oleic
acid (OA) +/- GPR40 inhibitor. DU145 cells were seeded at 20,000 cells/cm2 in tissue culture dishes.
The cells were incubated overnight and were then treated with 1 mM OA +/- 10 µM GW110 or vehicle
(DMSO; 5.2 µl). After 48 h of incubation, cells were collected, and proliferation (A) and viability (B) were
assessed by hemocytometer with trypan blue dye. No significant changes were observed among groups
compared to untreated group. Proliferation data are presented as fold over the untreated control group.
Both data sets are presented as the mean ± SD. The experiment was repeated at least twice with similar
results.

We next examined if Ca2+ was necessary for excess OA to produce its proproliferative effects on PCa cell growth. PC-3 cells were treated with 1 mM OA plus or
minus 10 µM Ca2+ chelator (BAPTA AM). OA alone or in the presence of BAPTA AM
treatment did not change the proliferation of PC-3 cells (Figure 4A). With regards to cell
viability, no significant difference was observed between groups in PC-3 cells (Figure
4B). We also examined RWPE-1 cells treated with OA plus or minus the BAPTA AM
chelator, but no consistency within experiments was observed (data not shown).
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Figure 4. PC-3 cell proliferation is not changed with 1 mM oleic acid (OA) treatment +/- Ca2+
chelator. PC-3 cells were seeded at 20,000 cells/cm2 in tissue culture dishes. The cells were incubated
overnight and were then treated with 1 mM OA +/- 10 µM BAPT AM or vehicle (DMSO; 1.9 µl). After 48 h
of incubation, cells were collected, and proliferation (A) and viability (B) were assessed by
hemocytometer with trypan blue dye. No significant changes were observed among groups compared to
untreated group. Proliferation data are presented as fold over the untreated control group. Both data sets
are presented as the mean ± SD. The experiment was repeated at least twice with similar results.

In additional to GPR40 and Ca2+ inhibitors, a PPARγ inhibitor was studied to test
whether PPARγ activity was necessary for excess OA-signaling effects on DU145 and
PC-3 cell proliferation and viability. RWPE-1 and DU145 cells displayed no effects on
cell growth and viability when the cells were treated with OA alone or in the presence of
GW9662 inhibitor (Figure 5 and Figure 6).
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Figure 5. Oleic acid (OA) +/- PPAR inhibitors do not change RWPE-1 cell proliferation. RWPE-1
cells were seeded at 20,000 cells/cm2 in tissue culture dishes. The cells were incubated overnight and
were then treated with 1 mM OA +/- 10 µM GW9662 or vehicle (ethanol; 6.9 µl). After 48 h of
incubation, cells were collected, and proliferation (A) and viability (B) were assessed by
hemocytometer with trypan blue dye. No significant changes were observed among groups compared
to untreated group. Proliferation data are presented as fold over the untreated control group. Both data
sets are presented as the mean ± SD. The experiment was repeated at least twice with similar results.

Figure 6. Proliferation and viability are not changed in DU145 cells treated with 1 mM oleic acid
(OA) +/- PPAR inhibitor. DU145 cells were seeded at 20,000 cells/cm2 in tissue culture dishes. The
cells were incubated overnight and were then treated with 1 mM OA +/- 10 µM GW9662 or vehicle
(ethanol; 6.9 µl). After 48 h of incubation, cells were collected, and proliferation (A) and viability (B)
were assessed by hemocytometer with trypan blue dye. No significant changes were observed among
groups compared to untreated group. Proliferation data are presented as fold over the untreated control
group. Both data sets are presented as the mean ± SD. The experiment was repeated at least twice
with similar results.
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Nonetheless, LNCaP cells exhibited a significant decrease in proliferation when
the cells were treated with OA alone, but not with PPARγ inhibitor, as compared to
untreated group (P-value =0.002; Figure 7A). No changes were observed in LNCaP cell
viability with OA in the presence or absence of PPARγ inhibitor (Figure 7B). A
significant decrease was found in the proliferation of PC-3 cells treated with OA alone or
in the presence of GW9662 (P-value <0.001; Figure 8A) whereas no changes were
observed in the viability of PC-3 (Figure 8B). Of note, the observed proliferation data
regarding LNCaP and PC-3 cells treated with OA alone are contrasted with what we
have found in the first experiments. TRAMPC2 cells have not been previously tested
with OA treatment alone or in the presence of PPARγ chemical inhibitors. We found that
OA alone treatment significantly decreased TRAMPC2 cell proliferation compared to
untreated group (P-value =0.043; Figure 9A). However, no changes were found in
viability of TRAMPC2 cells treated with the PPARγ chemical inhibitor alone or plus OA
(Figure 9B).
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Figure 7. Oleic acid (OA) treatment decreases LNCaP cell proliferation. LNCaP cells were seeded at
40,000 cells/cm2 in tissue culture dishes. The cells were incubated overnight and then were treated with 1
mM OA +/- 10 µM GW9662 or vehicle (ethanol; 6.9 µl). After 48 h of incubation, cells were collected, and
proliferation (A) and viability (B) were assessed by hemocytometer with trypan blue dye. *P-value =0.002
compared to untreated group. PPAR inhibitor treatment had no effects. Proliferation data are presented
as fold over the untreated control group. Both data sets are presented as the mean ± SD. The experiment
was repeated at least twice with similar results.

Figure 8. Proliferation of PC-3 cells treated with 1 mM oleic acid (OA) alone or with PPAR
inhibitor was decreased. PC-3 cells were seeded at 20,000 cells/cm2 in tissue culture dishes. The
cells were incubated overnight and were then treated with 1 mM OA +/- 10 µM GW9662 or vehicle
(ethanol; 6.9 µl). After 48 h of incubation, cells were collected, and proliferation (A) and viability (B)
were assessed by hemocytometer with trypan blue dye. *P-value <0.001 compared to untreated; **Pvalue =0.025 compared to 1 mM OA. Proliferation data are presented as fold over the untreated control
group. Both data sets are presented as the mean ± SD. The experiment was repeated at least twice
with similar results.
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Figure 9. Proliferation of TRAMPC2 cells is decreased with 1 mM oleic acid (OA) alone. TRAMPC2
cells were seeded at 20,000 cells/cm2 in tissue culture dishes. The cells were incubated overnight and
were then treated with 1 mM OA +/- 10 µM GW9662 or vehicle (ethanol; 6.9 µl). After 48 h of incubation,
cells were collected, and proliferation (A) and viability (B) were assessed by hemocytometer with trypan
blue dye. *P-value =0.043 compared to untreated group). Proliferation data are presented as fold over the
untreated control group. Both data sets are presented as the mean ± SD. The experiment was repeated
at least twice with similar results.

Since our data suggested that OA treatment exerted inconsistent growth results
in LNCaP and PC-3 cells, we expanded our work to test other FA, linoleic acid (LA) or
palmitic acid (PA), in excess for their effects on PCa proliferation and viability. PC-3
cells were treated with LA/BSA (ω-6 PUFAs) or PA/BSA (SFA) conjugate, which were
prepared in our lab as liquid versions were not commercially available. We included
liquid OA, ready to use from Sigma-Aldrich, or OA/BSA, conjugated in our lab, as a
control. LA/BSA treatment had no effects on the proliferation or viability of PC-3 cells
(Figure 10A and 10B). However, a significant reduction was found in PC-3 cell
proliferation treated with PA/BSA conjugate (P-value <0.001; Figure 11A); whereas, no
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changes were observed in viability of PC-3 cells treated with PA/BSA conjugate (Figure
11B). This observation was inconsistent with OA obtained from Sigma-Aldrich. These
results indicate that PA/BSA has inhibitory effects on PC-3 cells. We also examined the
effects of OA/BSA, prepared in our lab, on TRAMPC2 cells. We found that OA/BSA
conjugate significantly decreased TRAMPC2 cell proliferation compared to untreated
group (P-value <0.001; Figure 12A); however, the viability and metabolic activity of
TRAMPC2 cells were not changed in the presence of OA/BSA conjugate (Figure 12B
and 12C).
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Figure 10. Linoleic acid (LA)-conjugated BSA treatment does not affect the proliferation and
viability of PC-3 cells. PC-3 cells were seeded at 20,000 cells/cm2 in tissue culture dishes. The cells
were incubated overnight and were then treated with LA/BSA conjugation in a dose-response curve or
vehicle (1mM OA/BSA). After 48 h of incubation, cells were collected. Proliferation (A) and viability (B)
were assessed by hemocytometer with trypan blue dye. No statistically significant changes were
observed with LA/BSA treatment. Proliferation data are presented as fold over the untreated control
group. Both data sets are presented as the mean ± SD. The experiment was repeated at least twice with
similar results. V, vehicle (methanol + BSA); and LA/BSA, linoleic acid/bovine-serum albumin conjugation.
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Figure 11. Palmitic acid (PA)-conjugated BSA decrease the proliferation of PC-3 cells. PC-3 cells
were seeded at 20,000 cells/cm2 in tissue culture dishes. The cells were incubated overnight and were
then treated with PA/BSA conjugation in a dose-response curve or vehicle (1 mM liq. OA). After 24 h of
incubation, cells were collected. Proliferation (A) and viability (B) were assessed by hemocytometer
with trypan blue dye. *P-value <0.001 compared to untreated group. Proliferation data are presented as
fold over the untreated control group. Both data sets are presented as the mean ± SD. The experiment
was repeated at least twice with similar results. V, vehicle (methanol + BSA); Liq. OA, liquid oleic acid;
and PA/BSA, palmitic acid/bovine-serum albumin conjugation.
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Figure 12. Oleic acid (OA)-conjugated BSA decreases the proliferation of TRAMPC2 cells.
TRAMPC2 cells were seeded at 20,000 cells/cm2 in tissue culture dishes and a 96-well plate. The cells
were incubated overnight and were then treated with OA/BSA conjugation in a dose-response curve or
vehicle (1mM liq. OA). After 48 h of incubation, cells in dishes were collected, and an MTT assay was
performed on the 96-well plate. Proliferation (A) and viability (B) were assessed by hemocytometer
trypan blue dye. The cell metabolic activity (C) was assessed by MTT assay. *P-value <0.001
compared to untreated group. Data are presented as fold over the untreated control group. Both data
sets are presented as the mean ± SD. The experiment was repeated at least twice with similar results.
V, vehicle (methanol + BSA); Liq. OA, liquid oleic acid; and OA/BSA, oleic acid/bovine-serum albumin
conjugation
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The effects of OA alone or with GPR40 (GW1100), Ca2+ (BAPTA AM) or PPARγ
(GW9662) on PEDF expression in PCa cells
Our lab has previously investigated both extracellular and intracellular PEDF
levels in PCa cell lines using an in vitro obesity model simulated by excess OA
treatment. The previous data indicated that secreted PEDF levels were decreased with
1 mM OA treatment in RWPE-1, LNCaP, DU145 and PC-3 cells while cellular PEDF
levels were only suppressed in the two androgen-independent DU145 and PC-3 cells.
However, the molecular mechanisms through which excess OA down-regulates PEDF
in an in vitro obese microenvironment has not been revealed. In the present study, we
investigated if GPR40 was involved in OA-mediated PEDF suppression in PCa cells. In
addition, we asked if OA-suppressed PEDF expression was dependent on two potential
intracellular signaling pathways, Ca2+ and PPARγ. To test these mechanisms, LNCaP,
DU145, and PC-3 cells were treated with OA with or without GPR40, Ca2+ or PPARγ
inhibitors. Then, extracellular and intracellular PEDF levels were determined by ELISA.

Consistent with previous studies in the Doll Lab, ELISA showed that secreted
PEDF levels were significantly decreased in LNCaP cells treated with OA alone or in the
presence of GPR40 inhibitor while no differences in cellular PEDF levels were found
(Figure 13A and 13B). Similarly, a significant reduction in secreted PEDF levels was
identified in PC-3 cells treated with OA with or without the GPR40 inhibitor (Figure
14A). However, no effects on cellular PEDF were detected in PC-3 and DU145 cells
treated with OA alone or with the GPR40 inhibitor (Figure 14B and 15).
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Figure 13. Secreted PEDF levels are decreased in LNCaP cells treated with 1 mM oleic acid (OA)
alone or with GPR40 inhibitor. LNCaP cells were seeded at 40,000 cells/cm2 in tissue culture dishes.
The cells were incubated overnight and were then treated with 1 mM OA +/- 10 µM GW110 or vehicle
(DMSO; 5.2 µl). After 48 h of incubation, cells were collected, and secreted PEDF levels (A) and cellular
PEDF levels (B) were quantified by ELISA. *P-value <0.029 compared to untreated group. While OA plus
GW1100 inhibitor slightly increased secreted PEDF, this increase is not statistically significance (P-value
=0.057). #Some data values were below limit of detection and assigned a value of 0.31. Data are
presented as fold over the untreated control group. Both data sets are presented as the mean ± SD. The
experiment was repeated at least twice with similar results.

Figure 14. Secreted PEDF levels are decreased in PC-3 cells treated with 1 mM oleic acid (OA)
alone or with GPR40 inhibitor. PC-3 cells were seeded at 20,000 cells/cm2 in tissue culture dishes. The
cells were incubated overnight and were then treated with 1 mM OA +/- 10 µM GW110 or vehicle (DMSO;
5.2 µl). After 48 h of incubation, cells were collected, and secreted PEDF levels (A) and cellular PEDF
levels (B) were quantified by ELISA. *P-value <0.001 compared to untreated group. #Some data values
were below limit of detection and assigned a value of 0.004. Data are presented as fold over the
untreated control group. Both data sets are presented as the mean ± SD. The experiment was repeated
at least twice with similar results.
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Figure 15. Cellular PEDF levels are not changed in DU145 cells treated with 1 mM oleic acid
(OA) +/- GPR40 inhibitor. DU145 cells were seeded at 20,000 cells/cm2 in tissue culture dishes. The
cells were incubated overnight and were then treated with 1 mM OA +/- 10 µM GW110 or vehicle
(DMSO; 5.2 µl). After 48 h of incubation, cells were collected, and intracellular PEDF levels were
measured by ELISA. No significant changes were observed among groups compared to untreated
group. Data are presented as fold over the untreated control group. Both data sets are presented as
the mean ± SD. The experiment was repeated at least twice with similar results.

No significant changes were observed in the levels of cellular PEDF protein in
PC-3 cells cultured with OA alone or with the Ca2+ chelator (Figure 16). As shown in
Figure 17A, OA treatment alone decreased secreted PEDF and PPARγ inhibitor did not
rescue this effect. Neither OA treatment alone nor PPARγ inhibitor altered intracellular
PEDF levels in DU145 cells (Figure 17B). Collectively, our in vitro data indicated that
OA treatment reduced secreted PEDF levels in LNCaP, DU145, and PC-3 cells. This
observation is similar to our lab preliminary data. However, OA treatment with the
blocking agents of GPR40 or PPARγ did not rescue secreted PEDF in LNCaP, DU145,
and PC-3 cells. OA treatment alone did not affect cellular PEDF levels in DU145 and
PC-3 cells. These results contrasted with our lab preliminary data showing that cellular
PEDF levels decreased in OA-treated DU145 and PC-3 cells. Since OA did not
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suppress cellular PEDF levels, we would not expect these inhibitor molecules to have
an effect. While we did not find a decrease in PEDF levels in our current study
compared to our lab’s preliminary findings, several possible reasons for these
divergencies are discussed in-depth in the discussion section.

Figure 16. Cellular PEDF levels are not affected in PC-3 cells treated with 1 mM oleic acid (OA)
alone or with Ca2+ chelator. PC-3 cells were seeded at 20,000 cells/cm2 in tissue culture dishes. The
cells were incubated overnight and were then treated with 1 mM OA +/- 10 µM BAPT AM or vehicle
(DMSO; 1.9 µl). After 48 h of incubation, cells were collected, and intracellular PEDF levels were
measured by ELISA. No significant changes were observed among groups compared to untreated
group. Data are presented as fold over the untreated control group. Both data sets are presented as
the mean ± SD. The experiment was repeated at least twice with similar results.
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Figure 17. Secreted PEDF levels are decreased in DU145 cells treated with 1 mM oleic acid (OA)
alone or with PPARγγ inhibitor. DU145 cells were seeded at 20,000 cells/cm2 in tissue culture dishes.
The cells were incubated overnight and were then treated with 1 mM OA +/- 10 µM GW9662 or vehicle
(ethanol; 6.9 µl). After 48 h of incubation, cells were collected, and secreted PEDF levels (A) and
intracellular PEDF levels (B) were quantified by ELISA. *P-value <0.001 compared to untreated group.
#Some data values were below limit of detection and assigned a value of 0.028. Data are presented as
fold over the untreated control group. Both data sets are presented as the mean ± SD. The experiment
was repeated at least twice with similar results.
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IN VIVO AND EX VIVO MOUSE PROSTATE CANCER STUDIES
The weight and volume of TRAMPC2 xenograft tumor tissues increase in ob/ob
mice
Obesity and HFD have been associated with increased risk of progression and
death from PCa [11], [12]. In addition, PEDF expression levels are decreased in PCa
patient tissues [49]. However, in the published study, PEDF levels were not stratified by
patient weight or BMI. PEDF is a multifunctional protein that acts as a potent tumor
suppressor and a regulator of lipolytic activity [42], [46]. In our lab’s previous studies,
the 1 mM OA treatment reduced secreted PEDF in all PCa cell lines, LNCaP, PC-3, and
DU145, and in normal prostate epithelial cells, RWPE-1, (Doll et al. unpublished data).
In addition, 1 mM OA treatment also suppressed intracellular PEDF levels in DU145
and PC-3 while no effect on intracellular levels of PEDF was observed in RWPE-1 and
LNCaP (Doll et al. unpublished observation). Consistent with the OA treatment being
used as an obesity model, treated cells demonstrate a dose-dependent increase in lipid
accumulation (Doll et al. unpublished data). Conversely, rPEDF treatment (10 and 50
nM) reduced intracellular TG levels in basal and in OA-treated conditions, with a
concomitant increase in lipolysis (TG breakdown) in PC-3 cells (Doll et al. unpublished
data). Here, to investigate the impact of obesity on PEDF and pro-tumorigenic protein
expression in PCa, we used in vivo and ex vivo studies using a genetically obese model
(ob/ob mice) and a HFD model.
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In the genetically obese (ob/ob) model, TRAMPC2 (5.0 x 106) cells were
subcutaneously inoculated into the right flank of male WT and obese (ob/ob) mice.
When a subset of tumors reached the maximum growth limit, all mice were euthanized.
Then, tumor tissues and blood samples were collected. Ob/ob mice and WT mice were
fed a standard laboratory diet, and as expected, ob/ob mice gained more weight
compared to WT mice during the study. The average end body weight was significantly
higher in ob/ob mice (n= 20; 68.71 g ± 0.85) than WT mice (n= 10; 33.80 g ± 0.88;
Figure 18; P-value <0.001). As there was variability in tumor take rate and time to tumor
initiation, a subset of tumor xenograft harvested from ob/ob mice and WT mice was
used in the analysis (Figure 19A). We observed a significant increase in TRAMPC2
tumor weight in tumors growing in ob/ob mice (n= 20) compared to tumors growing in
WT mice (n= 10; P-value =0.018; Figure 19B). In addition, the TRAMPC2 tumor volume
was significantly higher in ob/ob mice, 4088.84 mm3, than WT mice, 1335.77 mm3 (Pvalue =0.018; Figure 19C). These results demonstrate that obesity promotes the growth
of TRAMPC2 xenograft in ob/ob mice.
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Figure 18. Body weights of wildtype (WT) and obese (ob/ob) mice on a standard laboratory diet.
Obese (ob/ob) mice (n= 20) and wildtype (WT) mice (n= 10) were fed a standard chow diet for 4
months. TRAMPC2 cells were subcutaneously injected into mice, and all tumors were collected when a
subset reached the maximum growth. Mouse weight was measured using a digital scale. As expected,
ob/ob mice showed a significant increase in body weight as compared to WT mice (*P-value <0.001
compared to WT mice). Data are presented as the mean ± SEM at 6 months of age.
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Figure 19. The weight of TRAMPC2 xenograft tumor growing in wildtype (WT) and obese (ob/ob)
mice. Ob/ob mice (n= 40) and WT (n= 40) were injected with TRAMPC2 PCa cells in the right flank,
and all tumors were collected when a subset reached the maximum growth. The collected tumors were
weighed using a digital scale. (A) Calculated tumor take rate. (B) TRAMPC2 tumor weight from ob/ob
mice compared to tumor weight from WT. (C) Tumor volumes were measured using digital calipers for
length and width measures, then calculated with the following formula: volume = length x width2 x 0.5.
*P-value <0.018 compared to TRAMPC2 tumor grown in WT mice. Data are presented as the mean
value ± SEM.
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HFD-fed Pbsn-Cre+PTENfl/fl mice gain more weight than CD-fed Pbsn-Cre+PTENfl/fl
mice
In addition to the genetically obese model, we also used the Pbsn-Cre+PTENfl/fl
PCa mouse model fed either a HFD or a CD for 16 weeks, beginning at 8 weeks of age.
The mouse body weight and food consumption were recorded weekly. We observed
that Pbsn-Cre+PTENfl/fl mice on a HFD gained significantly more weight over the 16
week diet as compared to a CD-fed mice (P-value <0.001; Figure 20A). As expected, at
the end of the study, the average mouse body weight was significantly increased in
HFD-fed Pbsn-Cre+PTENfl/fl mice (52 ±1.8) versus CD-fed mice (37 ±1.8 g; P-value
<0.001; Figure 20B). Based on a published literature observation [95], we expected that
the epididymal fat pad weight would be increased in mice on a HFD; however,
unexpectedly, we observed no difference in epididymal fat pad weight from PbsnCre+PTENfl/fl mice fed a HFD as compared to a CD (Figure 20C). Next, we measured
whether a HFD increased the weight of the mouse prostate. The mouse prostate lobes
(ventral, dorsolateral, and interior) were harvested and weighed. Interestingly, the
prostate lobes from HFD-fed Pbsn-Cre+PTENfl/fl mice were significantly heavier as
compared to the prostate lobes harvested from CD-fed mice (0.107 vs. 0.074 g; P-value
<0.042; Figure 21). Increased prostate weight is associated with an increase tumor
burden. Collectively, our data indicated that HFD increased the body weight and
stimulated tumor growth in Pbsn-Cre+PTENfl/fl mice.
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Figure 20. The body weight and epididymal fat pad weight of Pbsn-Cre+PTENfl/fl mice on control
diet (CD) and a high-fat diet (HFD). Pbsn-Cre+PTENfl/fl in C57BL/6 background mice, n=18 per group,
were fed either a CD (16.8% kcal from fat) or a HFD (60.3% kcal from fat) for 16 weeks, starting at 8
weeks of age. Mouse weight was measured weekly using a digital scale. (A) Mouse body weight graphed
over time. (B) Average weight at the end point of the experiment, 6 months of age. (C) Epididymal fat pad
weights (P-value =0.361). *P-value <0.001 compared to PCa mice fed a CD. Data are presented as the
mean value ± SEM.
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Figure 21. Prostate weight is increased in Pbsn-Cre+PTENfl/fl mice on a high-fat diet HFD vs a
control diet (CD). Pbsn-Cre+PTENfl/fl mice were fed either a CD (n=18) or a HFD (n=18) for 16 weeks,
starting at 8 weeks of age. The prostate lobes of mice were harvested when the mice are at 6 months
of age. *P-value <0.042 compared to Pbsn-Cre+PTENfl/fl mice fed a CD. Data are presented as the
mean value ± SEM.

Circulating PEDF levels are not increased in ob/ob mice and they are decreased
in HFD-PCa mice
Obese individuals have increased circulating PEDF levels [36], [38]. Our obese
mouse models gained significantly more weight than WT control mice (Figures 18 and
20). Therefore, we wanted to analyze PEDF expression because to date, circulating
PEDF levels have not been quantified in an obese PCa model. Herein, we measured
the serum PEDF levels in TRAMPC2 xenograft grown in ob/ob and WT mice. We
observed no significant differences in serum levels of PEDF in ob/ob mice versus WT
mice (Figure 22). This observation could indicate that some secretion of TRAMPC2
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tumors grown in ob/ob mice downregulates circulating PEDF since the regulation of
PEDF expression is not well understood. We further asked whether an obese
microenvironment in a HFD would show a similar result in circulating PEDF.

B

1200
1100
1000
900
800
700
600
500
400
300
200
100
0

#

TRAMPC2 xenograft
in WT mice

Serum PEDF levels (ng/ml)

Serum PEDF levels (ng/ml)

A

400
360
320
280
240
200
160
120
80
40
0
TRAMPC2 xenograft
in WT mice

TRAMPC2 xenograft
in ob/ob mice

n= 10

TRAMPC2 xenograft
in ob/ob mice
n= 20

Figure 22. Circulating PEDF concentrations are not increased in ob/ob mice versus wild-type (WT).
Mouse blood samples were collected using a retro-orbital bleeding technique from WT C57Bl/6 mice (n=
10) or ob/ob C57Bl/6 mice (n= 20) on a standard laboratory diet. Blood samples were incubated at RT at
least 30 min to allow clot to form. Then, the cellular components were removed by centrifugation, and
serum was collected. ELISA was performed to quantify PEDF protein. (A) PEDF levels in each serum
sample. (B) Average concentrations of PEDF levels. No significant differences in PEDF levels were
observed (P-value =0.224). #Data value for this sample was above the detection limit of the assay and
was assigned a value of 1050 ng/ml. Data are presented as the mean ± SEM.

We examined the circulating levels of PEDF in the Pbsn-Cre+PTENfl/fl mice were
fed either a HFD and or a CD for 16 weeks, beginning at 8 weeks of age. Mouse serum
was collected, and serum PEDF levels were measured. Data from ELISA revealed that
serum PEDF levels were significantly decreased in HFD-fed Pbsn-Cre+PTENfl/fl mice
(74.7 ng/ml ± 13.6) compared to CD-fed mice (133.4 ng/ml ± 12.4) (P-value <0.001;
Figure 23). To the best of our knowledge, this is the first study reporting a decrease in
circulating PEDF levels in HFD-fed PCa mice. In addition, this is the first report to
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indicate no significant increase in circulating PEDF levels in ob/ob mice bearing PCa
xenografts as compared to WT mice.
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Figure 23. HFD decreases circulating PEDF levels in PCa mice. Pbsn-Cre+ PTENfl/fl mice were fed
either a HFD (n= 8) or a CD (n= 8) for 16 weeks, beginning at 8 weeks of age. Mouse blood samples
were collected using a retro-orbital bleeding technique. Blood samples were incubated at RT at least 30
min to allow clot to form. Then, the cellular components were removed by centrifugation, and serum was
collected. An ELISA was performed to quantify PEDF protein. (A) PEDF levels in each serum sample
collected from mice. (B) The mean PEDF levels were a significantly decreased in HFD-fed Pbsn-Cre+
PTENfl/fl mice as compared to CD-fed Pbsn-Cre+ PTENfl/fl mice. *(P-value <0.001). Data are presented as
the mean ± SEM.

Serum leptin levels increase in HFD-fed Pbsn-Cre+PTENfl/fl mice
Increase in adipose tissue mass is known to increase secretion levels of
adipokines, such as leptin, into the blood [92]. Leptin is a hormone that regulates
appetite, energy expenditure, and body mass composition [92]. Doll et al. found that
obese patients with PCa displayed an increased in leptin levels, as expected; however,
there were no differences in PEDF levels in obese PCa patients as compared to lean
patients (Doll et al. unpublished study). Based on our mouse observation and these
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human data, we wanted to confirm that our HFD-fed Pbsn-Cre+PTENfl/fl mice had more
leptin. Therefore, we examined the serum levels of leptin since elevated leptin levels are
an indicator of adiposity. As shown in Figure 24, Pbsn-Cre+PTENfl/fl mice fed a HFD
had higher serum leptin levels (174.5 ng/ml ± 15.03) than mice fed a CD (30.56 ng/ml ±
7.2). This finding is consistent with our lab data showing that leptin levels are increased
in obese patients with PCa (Doll et al. unpublished study). This data is also consistent
with an increased adipose tissue mass in Pbsn-Cre+PTENfl/fl fed a HFD.
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Figure 24. HFD increases serum leptin levels in PCa mice. Pbsn-Cre+ PTENfl/fl mice were fed either a
HFD (n= 12) or a CD (n= 12) for 16 weeks, beginning at 8 weeks of age. Mouse blood samples were
collected using a retro-orbital bleeding technique. Blood samples were incubated at RT at least 30 min to
allow clot to form. Then, the cellular components were removed by centrifugation, and serum was
collected. A leptin ELISA was performed to quantify leptin levels. (A) Leptin levels in each serum sample
collected from mice. (B) The mean leptin levels between groups. *P-value <0.001 compared to Pbsn-Cre+
PTENfl/fl mice fed CD. Data are presented as the mean ± SEM.
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Tissue PEDF levels decrease in TRAMPC2 tumor growth in ob/ob mice
The effects of dietary HFD-induced obesity in PCa models on circulating PEDF
were largely unknown. Our preliminary studies suggest that in an in vitro obesity model,
simulated by using an OA lipid overload model, further suppresses secreted PEDF
expression in RWEP-1, LNCaP, PC-3, and DU145, (Doll et al. unpublished study). We
further explored this observation by examining the tissue PEDF levels in TRAMPC2
tumors grown in ob/ob mice. We found that tumor PEDF levels were significantly
decreased in TRAMPC2 tumors grown in ob/ob mice (9793 ± 1235.7) compared to
TRAMPC2 tumors grown in WT mice (13308 ± 1754; P-value =0.015; Figure 25).
These data suggested that PEDF suppression may be one mechanism of obesityinduced PCa progression.
B
40x103

ng PEDF / 5 ∝g total protein

ng PEDF / 5 ∝g total protein

A
36x103
32x103
28x103
24x103
20x103
16x103
12x103
8x103
4x103

#

0
TRAMPC2 xenograft
in WT mice

TRAMPC2 xenograft
in ob/ob mice

22.5x103
20.0x103
17.5x103
15.0x103
12.5x103

*

10.0x103
7.5x103
5.0x103
2.5x103
0.0
TRAMPC2 xenograft
in WT mice
n= 10

TRAMPC2 xenograft
in ob/ob mice
n= 20

Figure 25. Tissue PEDF levels are decreased in TRAMPC2 tumor tissues grown in ob/ob mice.
TRAMPC2 tumors were harvested from WT (n= 10) and ob/ob (n= 20) mice at 4 months post-injection.
Tumor tissues were homogenized, and protein levels were quantified with a Coomassie protein assay.
PEDF levels were measured by ELISA. (A) PEDF levels in each TRAMPC2 tumor tissues harvested from
mice. (B) The average PEDF levels between groups. *P-value =0.015 compared to TRAMPC2 tumor
tissue grown in WT mice. #Data value for this sample was below the detection limit of the assay and was
assigned a value of 156.8 ng PEDF / 5 µg. Data are presented as the mean ± SEM.
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Excess lipids do not increase the levels of PPARγ in TRAMPC2 tumor growth in
ob/ob mice
Although several mechanisms have been most intensively studied to understand
the association between obesity and PCa progression, the link between obesity and
PCa is still unclear. The insulin/insulin like growth factor-1 axis, sex hormones,
adipokine signaling, and pro-inflammatory cytokines have been well examined in PCa
[6], [96]. Our study was aimed to further examine several signaling pathways related to
PCa progression. PPARγ protein was detected in the nucleus and cytoplasm of PCa
cells and prostatic intraepithelial neoplasia, but no detection was observed in normal
prostate tissue samples [65], [66]. However, the levels of cytoplasmic PPARγ have not
been tested in obese patients with PCa. Here, we examined whether excess lipids in an
obese microenvironment increased the cytoplasmic levels of PPARγ in PCa tumor
tissue. Therefore, cytoplasmic PPARγ levels were evaluated in TRAMPC2 xenograft
tumors grown in obese ob/ob mice (n= 8) versus WT mice (n= 8). Western blot revealed
that cytoplasmic PPARγ was expressed in both TRAMPC2 tumor tissues grown in ob/ob
mice and WT mice, but no significant differences were observed (P-value =0.713;
Figure 26).

67

B
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2 TRAMPC2
xenograft
0.1 in WT mice

TRAMPC2 xenograft
in ob/ob mice

0.0
TRAMPC2 xenograft
in WT mice

TRAMPC2 xenograft
in ob/ob mice

Relative expression of PPARγ

Relative expression of PPARγ

A

0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
TRAMPC2 xenograft
in WT mice

TRAMPC2 xenograft
in ob/ob mice

n= 8

n= 8

Figure 26. An obese microenvironment did not alter the levels of PPAR . Tumor tissues were
homogenized, and protein levels were quantified with a Coomassie protein assay. Samples (30 µg) were
resolved on SDS-PAGE gels. The separated proteins were transferred to PVDF membrane by
electroblotting. Membranes were probed with anti- PPAR antibody, stripped and reprobed with anti-panactin antibody, which served as a control for protein loading. ( A) PPAR and pan-actin levels were
analyzed for each sample by densitometry. (B) The relative means of PPAR to pan-actin expression in
all samples were combined and analyzed by densitometry. (C) A representative Western blot analysis of
PPAR and pan-actin. Data are presented as the mean value ± SEM (P-value =0.713).

Excess lipids do not alter the activity of Wnt signaling in TRAMPC2 tumor growth
in ob/ob mice
We next examined the activity involvement of Wnt signaling in regulation of PCa
progression in an obese microenvironment. Thus, we investigated the activity of p-βcatenin Thr41/Ser45 in TRAMPC2 tumor xenograft tissues grown in ob/ob mice (n= 15)
versus WT mice (n= 10). In addition, we examined the possible effects of obesity on co68

receptor, LRP6, of Wnt signaling. Western blot analysis was performed on both
phosphorylation and non-phosphorylation status of both β-catenin and LRP6 in
TRAMPC2 tumor tissues in ob/ob mice and WT mice. Densitometry analysis of Western
blot showed that phosphorylated β-catenin Thr41/Ser45 were not changed in TRAMPC2
tumor tissues grown in ob/ob mice (n= 15) versus WT mice (n= 10; P-value =0.265;
Figure 27). Likewise, no significant changes were observed in the levels of pLRP6
ser1490 in TRAMPC2 tumor tissues from ob/ob mice (n= 8) compared to WT mice (n=
8; P-value =0.174; Figure 28).
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Figure 27. An obese microenvironment did not alter the levels of phosphorylated of β-catenin (pβcatenin). Tumor tissues were homogenized, and protein levels were quantified with a Coomassie protein
assay. Samples (30 µg) were resolved on SDS-PAGE gels. The separated proteins were transferred to
PVDF membrane by electroblotting. Membranes were probed with anti-pβ-catenin antibody, stripped and
reprobed with anti-β-catenin and pan-actin antibody. (A) p-β-catenin, β-catenin, and pan-actin levels were
analyzed for each sample by densitometry. (B) The relative means of p-β-catenin to β-catenin expression
in all samples were combined and analyzed by densitometry. (C) A representative Western blot analysis
of p-β-catenin, β-catenin, and pan-actin. Data are presented as the mean value ± SEM (P-value =0.265).
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Figure 28. An obese microenvironment did not alter the levels of phosphorylated of LRP6 (pLRP6). Tumor tissues were homogenized, and protein levels were quantified with a Coomassie protein
assay. Samples (30 µg) were resolved on SDS-PAGE gels. The separated proteins were transferred to
PVDF membrane by electroblotting. Membranes were probed with anti-pLRP6 antibody, stripped and
reprobed with anti-LRP6 and pan-actin antibody. ( A) PLRP6, LRP6, and pan-actin levels were analyzed
for each sample by densitometry. (B) The relative means of pLRP6 to LRP6 expression in all samples
were combined and analyzed by densitometry. (C) A representative Western blot analysis of p-LRP6,
LRP6, and pan-actin. Data are presented as the mean value ± SEM (P-value =0.174).
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The expression levels of cyclin D1 and the phosphorylation of Erk1/2 signaling
are not affected in TRAMPC2 tumors grown in obese versus WT mice
Since we did not observe a change in PPARγ and Wnt signaling pathways, we
sought to examine whether cyclin D1 and pErk1/2 expression levels were increased
with TRAMPC2 tumors grown in ob/ob mice (n= 8) compared to WT mice (n= 8). A
published study found increased cyclin D1 expression in the ventral prostate of TRAMP
mice fed a Western diet [34]. Cyclin D1 levels were evaluated using Western blot in
TRAMPC2 tumor tissues grown in ob/ob mice. Cyclin D1 levels were not further
increased in TRAMPC2 tumor tissues harvested from ob/ob mice compared to tumor
tissues from WT mice (P-value =0.474; Figure 29).

We next examined extracellular signal-regulated protein kinases 1 and 2
(Erk1/2), which are members of the mitogen-activated protein kinase super family. The
activity of Erk1/2 is involved in proliferation, survival, invasion, and angiogenesis in PCa
[97]. We examined whether the levels of pErk1/2 in TRAMPC2 tumor xenograft tissues
harvested from ob/ob mice (n= 15) and WT mice (n= 10) were increased. Western blot
analysis revealed that pErk1/2 was expressed in TRAMPC2 tumor tissues grown in
ob/ob mice and in WT mice but no significant changes were observed in our model (Pvalue =0.635; Figure 30). A reason for not finding an increase in p-Erk1/2 might be that
TRAMPC2 xenograft was grown in an obese microenvironment that lacked leptin.
Leptin has mitogenic effects on PCa cells through leptin stimulated increases p-Erk1/2
levels in DU145 and PC-3 cells [98]. Therefore, this could be the reason for not finding
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an increase in the activity of pERK1/2 in TRAMPC2 tumor tissue grown in ob/ob mice.
Other obese models should be tested.

B

Relative expression of cyclin D1

Relative expression of cyclin D1

A
1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
TRAMPC2 xenograft
in WT mice

TRAMPC2 xenograft
in ob/ob mice

1.20
1.05
0.90
0.75
0.60
0.45
0.30
0.15
0.00
TRAMPC2 xenograft
in WT mice
n= 8

TRAMPC2 xenograft
in ob/ob mice
n= 8

C
TRAMPC2
xenograft in
WT mice
1

2

3

TRAMPC2
xenograft in
ob/ob mice
4

5

6

7

8

Cyclin D1, 37 kDa
Pan-actin, 45 kDa

Figure 29. An obese microenvironment did not alter the levels of cyclin D1. Tumor tissues were
homogenized, and protein levels were quantified with a Coomassie protein assay. Samples (30 µg)
were resolved on SDS-PAGE gels. The separated proteins were transferred to PVDF membrane by
electroblotting. Membranes were probed with anti-cyclin D1 antibody, stripped and reprobed with antipan-actin antibody, which served as a control for protein loading. ( A) Cyclin D1 and pan-actin levels
were analyzed for each sample by densitometry. (B) The relative means of cyclin D1 to pan-actin
expression in all samples were combined and analyzed by densitometry. (C) A representative Western
blot analysis of cyclin D1 and pan-actin. Data are presented as the mean value ± SEM (P-value
=0.474).
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Figure 30. An obese microenvironment did not alter the expression levels of phosphorylated
Erk1/2 (pErk1/2). Tumor tissues were homogenized, and protein levels were quantified with a Coomassie
protein assay. Samples (30 µg) were resolved on SDS-PAGE gels. The separated proteins were
transferred to PVDF membrane by electroblotting. Membranes were probed with anti-pErk1/2 antibody,
stripped and reprobed with anti-pan-actin antibody, which served as a control for protein loading. (A) pErk1/2 and pan-actin levels were analyzed for each sample by densitometry. (B) The relative means of pErk1/2 to pan-actin expression in all samples were combined and analyzed by densitometry. (C) A
representative Western blot analysis of p-Erk1/2 and pan-actin. Data are presented as the mean value ±
SEM (p-value =0.635).
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AMPK signaling is activated in TRAMPC2 tumor growth in both WT and ob/ob
mice
As our data from signaling experiments did not reveal significant changes in
protein levels in TRAMPC2 tumor tissues growing in ob/ob mice versus WT mice, we
next studied the involvement of AMPK signaling. Even though AMPKα activity has been
found to be increased in human PCa tissues and in human PCa cell lines (LNCaP,
CWR22Rv1, DU-145 and PC-3) [99], the phosphorylation of AMPKα and total AMPKα
expression have not been investigated in obese patients with PCa. Here, we tested if
obesity increased the activity of AMPK signaling. The phosphorylation status of AMPKα
was examined in TRAMPC2 xenograft tumors grown in obese mice (n= 4) versus WT
mice (n= 4). Western blot analyses indicated that p-AMPKα was expressed in
TRAMPC2 tumor tissues grown in ob/ob mice. However, no differences in the ratio of pAMPKα to total AMPKα were observed in TRAMPC2 tumor tissues grown in ob/ob mice
versus WT mice (P-value =0.699; Figure 31). Therefore, an obese microenvironment
did not affect AMPK Thr172 phosphorylation status in TRAMPC2 tumor xenograft
tissues.

Several phosphothreonine and phosphoserine sites have been identified to
modulate AMPKα activity [100]. In addition, several isoforms of AMPK have been
identified [100]. In our study, we only examined p-AMPKα Thr172 and did not find a
difference between TRAMPC2 tumor grown in ob/ob mice versus WT mice. Future
studies should examine other phosphorylation sites or isoforms of AMPK that could
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reveal an additional link between obesity and PCa progression because the activity of
AMPKα Ser-486/491 was most recently reported to be associated with high advanced
of PCa [101].
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Figure 31. An obese microenvironment did not alter the ratio of phosphorylated AMPKα (pAMPKα) to total AMPKα. TRAMPC2 tumors were harvested from WT (n=4) and ob/ob (n=4) mice.
Tumor tissues were homogenized, and protein levels were quantified with a Coomassie protein assay.
Samples (30 µg) were resolved by SDS-PAGE. ( A) p-AMPKα, total AMPKα, and GAPDH levels were
analyzed by densitometry. (B) The relative means of p-AMPKα to total AMPKα expression in all
samples were combined and analyzed by densitometry. (C) A representative Western blot analysis of
p-AMPKα and total AMPKα was performed. GAPDH was included as a loading control. Data are
presented as the mean value ± SEM (P-value =0.699).
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The expression levels of SOD2 are decreased in TRAMPC2 tumor growth in ob/ob
mice
We next examined superoxide dismutase 2 (SOD2), a mitochondrial matrix
enzyme that is highly expressed in advanced PCa [102]. In PCa cells, the basal
expression levels of SOD2 were varied: SOD2 was 10-fold higher in PNT1A normal
human prostate cells than LNCaP cells and was also increased in PC-3 and DU145
[102]. The roles of SOD2 in obese patients with PCa has not been yet elucidated.
Herein, we examined whether excess lipids in an obese microenvironment induced
SOD2 expression. SOD2 levels were evaluated using Western blot in TRAMPC2 tumor
tissues grown in obese mice (n= 15) versus WT mice (n= 10). SOD2 levels were
significantly decreased in TRAMPC2 tumor tissues harvested from ob/ob mice
compared to tumor tissues from WT mice (P-value =0.018; Figure 32). Future studies
should focus on understanding how obese microenvironment reduced SOD2 levels in
PCa.
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Figure 32. An obese microenvironment decreased the expression levels of SOD2. Tumor tissues
were homogenized, and protein levels were quantified with a Coomassie protein assay. Samples (30 µg)
were resolved on SDS-PAGE gels. The separated proteins were transferred to PVDF membrane by
electroblotting. Membranes were probed with anti-SOD2 antibody, stripped and reprobed with anti-panactin antibody, which served as a control for protein loading. (A) SOD2 and pan-actin levels were
analyzed for each sample by densitometry. (B) The relative means of SOD2 to pan-actin expression in all
samples were combined and analyzed by densitometry. (C) A representative Western blot analysis of
SOD2 and pan-actin. *P-value =0.018 compared to TRAMPC2 tumor grown in WT mice. Data are
presented as the mean value ± SEM.
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The expression levels of SPT are decreased in TRAMPC2 tumor growth in ob/ob
mice.
The final molecule that we investigated in our study was serine
palmitoyltransferase (SPT), which is the rate limiting enzyme in sphingolipid synthesis.
SPT expression has been identified in normal human prostate tissue [103], but its
expression has not been reported in PCa patient tissues. To our knowledge, this is the
first study to report the expression levels of SPT in TRAMPC2 xenograft tumor grown in
ob/ob mice (n= 8) versus WT mice (n= 8). Western blot analysis revealed that SPT
levels were significantly decreased in TRAMPC2 tumor tissues grown in ob/ob mice as
compared to WT mice (P-value =0.050; Figure 33). Thus, obesity due to a genetic
alternation decreased SPT levels in TRAMPC2 xenograft tumor.
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Figure 33. An obese microenvironment decreased the levels of SPT. Tumor tissues were
homogenized, and protein levels were quantified with a Coomassie protein assay. Samples (30 µg) were
resolved on SDS-PAGE gels. The separated proteins were transferred to PVDF membrane by
electroblotting. Membranes were probed with anti-SPT antibody, stripped and reprobed with anti-panactin antibody, which served as a control for protein loading. (A) SPT and pan-actin levels were analyzed
for each sample by densitometry. (B) The relative means of SPT to pan-actin expression in all samples
were combined and analyzed by densitometry. (C) A representative Western blot analysis of SPT and
pan-actin. *P-value =0.050 compared to TRAMPC2 tumor grown in WT mice. Data are presented as the
mean value ± SEM.
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DISCUSSION

Obesity and cancer are both global public health concerns, with obesity
incidence drastically increasing over the past three decades [104]. If a PCa patient is
obese, he is at a higher risk of aggressive disease and more likely to die from the
disease as compared to a lean PCa patient [11], [12]. However, the molecular
mechanisms underlying obesity-fueled PCa progression is unclear. Our studies were
aimed to reveal a mechanistic insight into this association. Previously, our lab was able
to simulate an in vitro obese model by treating PCa cells with excess OA to evaluate the
underlying mechanisms. In this model, the proliferation and metabolic activity of PCa
cells was increased as determined by direct cell counts and MTT assay (Doll et al.
unpublished observation). In addition, PEDF levels were suppressed in PCa cells
treated with excess OA. PEDF is a multifunctional protein that acts as a potent tumor
suppressor via its anti-angiogenic and anti-proliferative inhibitory activities [42]. PEDF
has been identified as a novel regulator of lipid metabolism through binding and
activating ATGL [46], [47]. However, circulating and tissue PEDF levels have not been
previously examined in vivo under obese conditions in PCa.

In our in vivo study, we observed a significant increase in TRAMPC2 tumor
volume and in tumor weight, in tumors grown in ob/ob mice as compared to tumors
grown in WT mice (Figure 20). Consistent with our observation, Ribeiro et al. found a
significant increase in the tumor weight of RM1 PCa xenografts grown in ob/ob mice
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compared to RM1 tumors grown in WT mice [35]. These results suggested that a
genetically obese microenvironment accelerates tumor growth of these PCa xenografts.
In our in vivo dietary study, we expected that the epididymal fat pad weight would be
increased in mice placed on a HFD compared to CD-fed mice since the increase of the
epididymal fat pad weight is previously reported in HFD-fed mice [32], [95]; however, as
compared to the CD-fed mice, in our study, there were no differences in the epididymal
fat pad weight, and this is an opposite to what we expected. This observation suggests
that HFD-fed mice could promote PCa growth through a mechanism independent of
epididymal fat tissues. In addition, it could be that mice did not deposit excess fats from
HFD in epididymal fat pad. Therefore, a comprehensive fat depot evaluation should be
performed in a HFD mouse model of PCa. In addition, the start age point and duration
of time that mice are fed a HFD should be evaluated since there is no standardized
protocol for the start age point and length of time that mice stay on a HFD. Chen et al.
fed Pbsn-Cre+PTENfl/fl mice a HFD, starting at the age of 12 months for 3 months
although they did not report epididymal fat pad weight [33]. In contrast, we fed our
Pbsn-Cre+PTENfl/fl mice a HFD, beginning at the age of 2 months for 4 months.

Our lab previously demonstrated that PEDF-KO mice developed prostatic
hyperplasia that evolves to cancer when these mice were fed a HFD (Doll et al.
unpublished observation). However, it is unknown how the loss of PEDF expression
under an obese microenvironment promotes progression of the prostatic hyperplasia to
cancer. Interestingly, in other studies, an obese microenvironment increased circulating
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PEDF levels in ob/ob mice and HFD-mice [36], [38]. To our knowledge, the circulating
and tissue levels of PEDF in obese mice with PCa has not been previously evaluated.
Additionally, the functional role of PEDF as an anti-tumor has not been examined in
obese individuals with PCa. Herein, we examined if an obese microenvironment alters
circulating PEDF levels and decreases PEDF levels in TRAMPC2 tumor tissue. In the
TRAMPC2 xenograft study, we did not identify an increase in serum PEDF levels in
obese (ob/ob) mice as compared to WT mice (Figure 22). A possible explanation for
not finding increased circulating PEDF in our ob/ob mice is that secretions from
TRAMPC2 xenograft tumors led to lower PEDF levels in ob/ob mice since the increased
serum PEDF levels are well-documented in mouse obesity models [36], [38]. In
addition, the major source of circulating PEDF is the liver that could be affected in the
presence of TRAMPC2 tumor xenografts [41]. Li et al. injected mice with squamous cell
carcinoma (SCC) and evaluated the liver functions [105]. They found that mice with
SCC xenograft tumors showed hepatomegaly and liver injury. In addition, they identified
reduced albumin/globulin ratios, elevated serum TG, increased hepatic mRNA levels of
inflammatory cytokines, and decreased fatty acid oxidation in the liver of mice with SCC
xenografts [105].

Interestingly, when we induced obesity by using a HFD in Pbsn-Cre+PTENfl/fl
mice, we found that the serum levels of PEDF were significantly reduced in HFD-fed
PCa mice compared to CD-fed mice (Figure 23). Our findings contrasted with other
published studies regarding increased circulating PEDF levels in HFD-fed mouse model
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[36], [38]. In non-tumor bearing mice, a HFD increased circulating PEDF levels that
contributed to insulin resistance [36], [38]. Specifically, the plasma PEDF levels were
significantly increased (15 ng/ml) in non-tumor mice fed a HFD compared to mice fed a
low chow fat (4.9 ng/ml) [38]. Conversely, in our study, HFD-fed PCa mice showed high
levels of serum PEDF levels (74.7 ng/ml ± 13.6) versus CD-fed mice (133.4 ng/ml ±
12.4). It has been proposed that the elevated circulating PEDF is a compensatory
mechanism in response to the increased body weight since its expression is decreased
with the body weight loss [36]. To confirm that increased PEDF is a compensatory
mechanism, a recent report showed that HFD-fed mice treated with PEDF showed
decreased body weight, increased lipolytic activity, and improved insulin sensitivity
[106]. Another reason may be due to the variation of PEDF isoforms. There are two
identified isoforms, PEDF-1 and PEDF-2, with different functional roles. PEDF-2 has
more a potent anti-tumor activity than PEDF-1 [43]. Also, they have different charge and
molecular mass: PEDF-1 is 46,063 ± 13 Da and PEDF-2 is 47,176 ± 87 Da [43]. Further
studies are needed to distinguish which isoform is affected by obesity.

We also examined tumor PEDF levels in TRAMPC2 tumor tissues grown in
ob/ob mice versus WT mice. A significant reduction in PEDF levels was found in
TRAMPC2 tissues grown in ob/ob mice compared to tumor tissues harvested from WT
mice (Figure 25). The reduction of PEDF suggests that PEDF could have an anti-tumor
effects in obese conditions since a significant increase in TRAMPC2 tumor volume and
weight was observed in tumors growing in ob/ob mice compared to tumors growing in
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WT mice. However, the mechanisms through which an obese microenvironment
decreases tissue PEDF are still unknown.

Of note, while we found a significant reduction in the serum levels of PEDF in
HFD-fed Pbsn-Cre+PTENfl/fl mice, we did observe a significant increase in serum leptin
levels in HFD-fed Pbsn-Cre+PTENfl/fl mice as expected (Figure 24). In a pilot study in
our lab, it was observed that obese patients with PCa showed an increased in leptin
levels, but not in PEDF levels (Doll et al, unpublished study). An association between
these two molecule’s expression was published in the context of angiogenic regulation
[107], [108]. Leptin treatment increased secreted vascular endothelial growth factor,
transforming growth factor-β1, and basic fibroblast growth factor in DU145 and PC-3
cells [109]. Additionally, leptin can stimulate angiogenesis in endothelial cells [110];
however, PEDF is a potent anti-angiogenic protein, and rPEDF treatment of PC-3 tumor
xenografts in nude mice decreased stromal vasculature and induced apoptosis [49].
Importantly, Yamagishi et al. found that PEDF inhibited leptin-induced angiogenesis of
microvascular endothelial cells [107]. Likewise, a recent published study showed that
HFD-fed mice treated with PEDF showed a decrease in the serum leptin levels [106].

In our studies, we examined other pathways related to PCa progression. We did
not find changes in the activity and/or expression levels of PPARγ, p-β-catenin, pLRP6,
pErk1/2, cyclin D1, and p-AMPKα in TRAMPC2 tumor tissues grown in ob/ob mice
versus WT mice. However, we did find a significant decrease in SOD2 and SPT
84

signaling pathways in TRAMPC2 tumor tissues grown in ob/ob mice versus WT mice
(Figure 32 and 33).

SOD2 is an enzyme localized in the mitochondrial matrix to catalyze the
conversion of superoxide anion (O2•−) to hydrogen peroxide (H2O2) that is further
metabolized to water by other antioxidants such as catalase and glutathione peroxidase
[111]. Thus, SOD2 controls the concentration of reactive oxygen species (ROS), which
is associated with increased oxidative DNA damage in PCa cells [112]. Interestingly,
PEDF and its 44 mer peptide have demonstrated antioxidant activity via increasing the
activity of total SOD and decreasing ROS in cardiomyocytes, H9c2 cells [113]. Gong et
al. showed in pancreatic intraepithelial neoplasia (PanIN) cells that PEDF specifically
induced SOD2 expression [114]. Thus, if PEDF regulates SOD2 activity in PanIN cells,
then it is possible that decreased PEDF in PCa tissues could lead to decreased SOD2
activity.

SOD2 expression levels, evaluated by immunohistochemistry, are decreased in
PIN and PCa patient tissues compared to benign epithelium tissues [115]; however,
others reported that the protein levels of SOD2, analyzed by Western blotting and by
immunocytochemistry, are highly expressed in PCa tumor tissues in advanced and
middle stage of disease [102], [116]. However, none of these studies stratified PCa
patients by BMI. A possible explanation of these conflicting findings was stated in Miar
et al.’s study [116]. They explained that as different mutations occur in low-grade versus
85

high-grade PCa, this could be reason for different levels of SOD2 in PCa tissues [116].
It could be also that increased SOD2 expression in advanced PCa cancer is a
compensatory mechanism against the increased oxidative stress [117].

Previous studies showed that obesity reduced SOD2 levels in the liver and
kidney and increased oxidative stress in the form of ROS in mouse plasma and adipose
tissues [118], [119]. In a tumor setting, the decreased SOD2 levels could result in
increased ROS generation that could promote tumor progression. In addition, obesity
increases ROS production in PCa cells [112], [120], but a mechanism was not
described. If SOD2 levels are decreased, then the resulting increases in ROS would
lead to increased pro-inflammatory cytokines [95], [96], [121]. It could be that obesity
mediates suppression of SOD2 expression results in increased ROS which in turn
increased pro-inflammatory cytokines. A recent study showed that overexpression of
SOD2 reduced inflammation [122] while increased chronic inflammation impaired SOD2
function [123]. Together, downstream pathways altered by decreased SOD2
expression, including inflammatory responses and ROS homeostasis, should be further
investigated.

To our knowledge, this is the first study to report the expression levels of SPT in
PCa TRAMPC2 tumor xenograft. We demonstrated that SPT expression was
significantly reduced in TRAMPC2 xenograft tissues grown in ob/ob mice as compared
to WT mice. Reduced SPT levels could be one mechanism of obesity to protect cancer
86

cells against lipotoxicity since SPT is involved in the process of ceramide production
that acts as a lipid mediator of apoptotic signaling cascade [124], [125]. Lipotoxicity is a
pathway through which an excess lipid accumulation in non-adipose tissues leads to
cellular dysfunction and death through lipoapoptosis [126]. Ceramide can be generated
via the hydrolysis of sphingomyelin by sphingomyelinases and via condensation of
serine and palmitoyl‐CoA, which is catalyzed by SPT and ceramide synthase enzymes,
respectively [127]. The activity of these enzymes has not been examined in obese
individuals with PCa.

Ceramide has been identified as an anti-tumor lipid, stimulating apoptotic
signaling in various cancer cell types, including PCa [124], [125], [128]. The pathways
activated by ceramide include the stress-activated protein kinase (SAPK/JNK) pathway,
apoptotic caspases pathway, and Fas cell surface death receptor pathway [124], [125],
[128]. Wang et al. showed that the anticancer agent, fenretinide N-(4hydroxyphenyl)retinamide;4-HPR), stimulated the formation of ceramide in LNCaP and
PC-3 cells via increasing the activity of SPT resulting in enhancing apoptosis in these
cells [125]. Another study by Fillet et al. displayed that the exogenous treatment of
ceramide induced apoptosis in both human colon cancer (HCT116) and human ovarian
carcinoma (OVCAR-3) cell lines [129]. They specifically showed that C2- and C6ceramides increased the activity of caspase-3 and mitochondrial cytochrome c in
HCT116 and OVCAR-3 cells [129]. In human promyelocytic leukemia cells (HL-60)
treated with ceramide, Kim et al. showed an induction of cell death through the
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mitochondrial pathway [130]. Specifically, ceramide induced cytochrome c release and
increased activity of Bax, a pro-apoptotic factor, in HL-60 cells [130].

These results indicate that elevation of ceramide levels in tumor cells can result
in cell death; however, reduced SPT could reduce ceramide production in TRAMPC2
tumor tissues grown in ob/ob mice which suggests that TRAMPC2 tumors in an obese
microenvironment are protected from lipotoxicity and lipoapoptosis. Moreover, the loss
and/or reduction of SPT expression has been found to increase the formation of lipid
droplet and to alter lipid metabolism. In hereditary sensory neuropathy type 1 (HSN-1),
which is an autosomal dominant neurodegenerative disease, caused by a mutation in
SPT gene, Marshall et al. showed increases in the number of lipid droplets and changes
in lipid metabolism in HSN-1 patient-derived lymphoblasts [131].

Our lab’s previous data showed that in an in vitro obesity model of PCa, excess
OA suppressed both secreted and cellular PEDF levels in DU145 and PC-3 cells.
Herein, we investigated whether excess OA activated GPR40-induced Ca2+ signaling
and/or PPARγ signaling to decrease PEDF expression in normal prostate cell and PCa
cell lines. In addition, we explored whether excess lipids, due to obesity and HFD
microenvironments, increased pro-tumorigenic signaling activity and reduced PEDF
expression.

88

In the present study, the proliferation and viability of PCa cells treated with OA
alone or plus chemical inhibitors were assessed as these features are an indicator of
tumor progression. RWPE-1 and DU145 proliferation were not affected with OA
treatment at 1 mM alone while the proliferation of TRAMPC2 was reduced with OA
treatment alone. All cells exposed to GPR40 or PPARγ chemical inhibitor alone or in the
presence of OA showed no effects on proliferation. Published studies in OA treated PCa
cells vary. Inconsistent with our observation, Hughes-Fulford et al. found a reduction in
proliferation of PC-3 cells treated with OA treatment at 0.1 mM using used CyQUANT
cell proliferation assays [132]; other studies reported that an increase in PC-3
proliferation using MTT assay with OA treatment at 0.1-0.4 mM [94], [133]. Hagen et al.
demonstrated no changes on DU145 proliferation using the MTT assay when the cells
were cultured with OA [133], while Liotti et al. found increased DU145 proliferation with
OA [94]. These inconsistent findings in PCa cell proliferation could be due to use of
different OA doses, different incubation times, and different OA preparations.

Viability of RWPE-1, LNCaP, DU145, and PC-3 cells was not affected with 1 mM
OA treatment alone or in the presence of GPR40, Ca2+, or PPARγ chemical inhibitors
compared to untreated group. Similar to our observation, Gasmi et al. treated RWPE-1,
LNCaP, and PC-3 cells with two different forms of OA, which were cis- and transvaccenic acids, at 0.1 mM and found no changes on cell viability in any of the cell lines
[134]. Hagen et al. treated LNCaP, DU145, and PC-3 cells with 0.1 mM OA, and viability
of these cells was evaluated. They found no effects on LNCaP and PC-3 cell viability
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while a reduction in DU145 cell viability was observed [133]. These results are
consistent with our observation in LNCaP and PC-3 cell viability, but not in DU145 cell
viability. Together, our data demonstrated that no effects on viability were produced
from OA treatment alone or with chemical inhibitors of GPR40 or PPARγ on PCa cells.

The potential explanations for the variability associated with FA treatment within
our study and other published studies are that this variability could be associated to
human-, device-, dosage-, assays- or sample preparation-differences. In our study, we
starved PCa cells for 4 h before adding FA treatment while Liotti et al. starved PCa cells
for 16 h [94]. In addition, PCa cells are able to grow in different culture medium
conditions. DU145 and PC-3 cells have the ability to grow in DMEM or RPMI media,
and this is a factor added to these discrepancies. Hughes-Fulford et al. and we grew
PCa cells in RPMI media [132] while Liotti et al. grew PCa cells in DMEM media [94].
Another important factor is that various FA preparations and concentrations used in
PCa studies significantly contribute to divergent results. In our study, we used different
lots of OA that produced inconsistent effects on PCa growth response since we were
unable to find similar results in LNCaP and PC-3 cell proliferation. Previously, our lab
found a decrease in viability of LNCaP and PC-3 cells treated with OA treatment [135]
while we did not find a change in LNCaP and PC-3 cell viability treated with the same
OA treatment but the lot numbers of OA are not the same.
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Our lab’s previous data suggested that after 48 h of OA treatment, a suppression
in cellular PEDF expression was identified in two androgen-independent PCa cells,
DU145 and PC-3 cells; conversely, no changes were found in RWPE-1 and LNCaP
cells. Secreted PEDF were decreased in RWPE-1, LNCaP, DU145, and PC-3 cells
treated with excess OA (Doll et al. unpublished observation). In our studies, we sought
to determine the molecular mechanisms through which excess OA suppresses PEDF
expression in PCa cells. However, we did not find that OA bound to GPR40 that
activates Ca2+ and/or PPARγ to exert its effects on PEDF suppression.

Of significant note, we observed no changes in cellular PEDF levels in our
current study, which contrasts to our lab’s preliminary studies in DU145 and PC-3 cells
treated with OA alone. One of the important reasons for these discrepancies is that the
type of growth media for DU145 and PC-3 cells was changed from DMEM to RPMI due
to growth issues. In breast cancer cell Lines (MCF7, MDA-MB-436, and SkBr3), using
different types of growth media (DMEM and RPMI-1640) were found to have differences
in phenotypic markers and growth rates [136]. Thus, it could happen that the metabolic
responses to OA are altered in PCa cells with changing the media from DMEM to RPMI.
In addition, we purchased a prepared OA from Sigma that is ready to use. We noticed
that OA treatment has different effects on PCa viability as determined in the current and
previous studies conducted in our lab [135]. There could be issues with differences in
the quality of OA batch-to-batch. Future study should evaluate batch-to-batch quality
consistency of OA.
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CONCLUSION AND FUTURE DIRECTIONS

Conclusion
The aim of this study was to investigate whether excess lipids, in obesity and
HFD microenvironments, alter lipid metabolism, which in turn, decreases PEDF
expression and increases pro-tumorigenic activity in PCa. We included two in vivo
models of obesity: the genetically obese model (ob/ob) and a HFD-induced obese
model. We also used an excess OA model to simulate obesity in vitro. These models
were used to evaluate how excess lipids in an obese microenvironment promoted PCa
progression and decreased anti-tumor PEDF protein. We examined GPR40, Ca2+, and
PPARγ as potential molecular mechanisms for OA to suppress PEDF. However, our
data indicated that inhibition of GPR40 and PPARγ did not abolish OA-induced
suppression of secreted PEDF expression in PCa cells (LNCaP, PC-3, and DU145)
compared to untreated group. These results did not support that OA exerts its effects on
secreted PEDF suppression through activation of GPR40 and PPARγ.

In the in vivo obese (ob/ob) mouse study, our data indicated that serum PEDF
levels were not increased in ob/ob mice compared to WT mice; whereas, tissue PEDF
levels were significantly decreased in TRAMPC2 tumor tissues grown in ob/ob mice
versus WT mice. In HFD-fed Pbsn-Cre+PTENfl/fl PCa mice, the serum levels of leptin
and PEDF were quantified. We found that leptin was increased while PEDF was
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decreased. Leptin displays a pro-tumorigenic activity; whereas, PEDF exhibits antitumorigenic activity. No changes were observed in PPARγ, β-catenin, pErk1/2, cyclin
D1, and AMPKα signaling pathways. However, a significant decrease was observed in
SOD2 and SPT signaling pathways in TRAMPC2 tumor tissues grown in ob/ob mice
versus WT mice.

Future direction
Future studies are required to fully understand how an obese microenvironment
decreases PEDF, SOD2, and SPT expression in PCa. One of the future directions is to
explore the effects of PEDF treatment on inhibition of PCa progression in an obese
microenvironment. For this set of studies, we will use PEDF-KO mice and WT mice fed
a CD or a HFD, and ob/ob mice fed a CD. All mice will be then injected with mouse PCa
xenografts and treated with exogenous PEDF or vehicle. Tumor tissue growth,
metastasis, and the underlying molecular mechanisms through which PEDF treatment
inhibits PCa progression should be investigated. Specifically, we will evaluate if PEDF
functions as an activator of the intrinsic apoptotic signaling through upregulated BAX
and BCL-2 proteins and as an anti-inflammatory activator via reduced interleukin-6 and
tumor-necrosis factor-α levels. In addition, we will examine if PEDF as an antioxidative
stress protein through decreased ROS and increased SOD2 levels. These experiments
will identify a novel relationship between PEDF and obese PCa suppression and
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determine if PEDF has anti-obesity properties. Therefore, this study could identify PEDF
as a new and effective therapy for obese PCa patients.

Our study is the first study to report SOD2 in obese model of PCa. Evaluating the
expression levels of SOD2 in obese patients with PCa is an important future step. While
there are a few studies that reported the levels of SOD2 in PCa patients [102], [116],
further investigation of the effects of antioxidant SOD2 treatment such as manganese
(to activate SOD2) or overexpression of SOD2 in preventing obesity-driven PCa
progression should be conducted.

To our knowledge, this is the first preliminary study to identify the decreased
levels of SPT in obese model of PCa. Future studies should further investigate the
regulation of ceramide pathway in an obese microenvironment. For this set of
experiments, we will include human PCa xenografts in nude mice that will be placed on
a CD or a HFD. In addition, we will include Pbsn-Cre+-PTENfl/fl PCa model fed either a
CD or HFD as well as TRAMPC2 xenografts in WT mice and ob/ob mice. Then, all mice
will be treated with nanoliposomal C6-ceramide or liposomal-C8 ceramide treatment as
described previously [137]. Tumor tissues will be collected and analyzed for markers of
apoptotic signaling cascades and for ceramide signaling pathways such as SPT and
ceramide synthase enzymes. If this experiment shows a significant reduction in tumor
growth in obese models, this could be used as an effective therapy for obese PCa
patients.
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